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INTRODUCTION 
The focus of this project involved the study of antiviral 
drug resistance in human cytomegalovirus (HCMV}. The project 
was divided into three sections: l} development of a rapid 
antiviral susceptibility assay for HCMV, 2} isolation of a 
ganciclovir (GCV}-resistant clinical strain of HCMV, and 3} 
construction of a GCV-resistant mutant of HCMV. 
In order to more rapidly screen for HCMV anti viral 
susceptibility, an in situ ELISA was developed. Evaluation 
of the ELISA showed that it 1} was more rapid than the 
standard plaque reduction assay (PRA}, 2} objectively measured 
viral replication, and 3} more accurately revealed drug 
resistance. 
Clinical isolates of HCMV from transplant patients at 
Loyola University Medical Center were collected and screened 
for GCV-susceptibility using the ELISA assay. One isolate, 
H51856, was shown to be GCV-resistant. Further experiments 
revealed that <1% of the isolate was actually GCV-resistant. 
Clones of the GCV-resistant subpopulation were purified. The 
ELISA assay revealed that the clones were also cross-resistant 
to DNA polymerase inhibitors phosphonoformic acid and 
phosphonoacetic acid. GCV anabolism studies showed that the 
clones had wild-type GCV-kinase activity which is necessary 
for activation of the drug. Therefore, a mutation in the 
viral DNA polymerase was probably responsible for drug 
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resistance. Sequence analysis of the DNA polymerase gene of 
the GCV-resistant clones was performed to locate the possible 
mutation. 
Construction of a drug-resistant mutant of HCMV was 
carried out by first introducing a single base substitution 
in the wild-type HCMV AD169 DNA polymerase gene. Evidence 
exists suggesting that this substitution may result in drug 
resistance in herpesviruses. Recombination experiments were 
performed using the mutagenized plasmid and wild-type HCMV 
AD169 DNA. Although numerous experiments were unsuccessful, 
several drug-resistant plaques were eventually isolated and 
are currently being purified. 
Since significant amino acid homology exists between the 
HCMV and HSV DNA polymerase proteins, recombination 
experiments were performed using the mutagenized plasmid and 
wild-type HSV-1 KOS DNA. Sequence analysis of the DNA 
polymerase gene of a drug-resistant plaque suggested that the 
clone was not a recombinant, but a spontaneous mutant. 
Finally, a GCV-resistant clinical isolate of HSV-2 was 
characterized. In contrast to the HCMV results, experiments 
with the HSV-2 mutant suggested that a mutation in the gene 
responsible for drug phosphorylation was the most probable 
cause of drug resistance. 
LITERATURE REVIEW 
Structure and molecular characteristics of HCMV and HSV. 
Human cytomegalovirus (HCMV) and herpes simplex virus type 1 
(HSV-1) and type 2 (HSV-2) are members of the herpesvirus 
family. Herpesvirus particles characteristically consist of 
an icosahedral capsid containing a linear, double-stranded DNA 
genome (3,24,84). The nucleocapsid is surrounded by the 
tegument, an amorphous layer of viral proteins, which in turn 
is enclosed by a lipid envelope carrying surf ace 
glycoproteins. 
The genome sizes of HCMV and HSV are approximately 230 
and 152 kilobase pairs (kb), respectively (14,84). The HSV 
and HCMV genomes are composed of two covalently joined 
segments, the long (L) and short (S) regions (3,84). The L 
region consists of a unique sequence (UL) flanked by a pair 
of oppositely orientated repeat elements. Similarly, the S 
region consists of the Us sequence flanked by its own repeat 
elements. Since the L and S components can invert during 
replication, virions contain any one of four isomers of the 
viral genome. 
Growth of HCMV and HSV. HSV has a broad host range and 
can infect most tissue culture cell lines that have been 
derived from vertebrate species (24). The replication cycle 
is fairly short (approximately 24 h), resulting in release of 
3 
virions into the culture medium. 
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In contrast, HCMV is 
species-specific and efficiently replicates very slowly (up 
to 72 h) only in certain permissive human primary cell 
cultures (116). The virus is generally cell-associated with 
little release of virus into the culture medium. Repeated 
passage of primary HCMV isolates may result in increased 
titers of virus in the culture medium. 
Both HSV and HCMV bind to as of yet unidentified 
receptors on the permissive cell membrane. After attachment, 
fusion between the viral envelope and the cell membrane allows 
entry of the nucleocapsid into the cytoplasm followed by 
release of the viral DNA. 
Once the viral DNA genome reaches the cell nucleus, 
expression of viral genes occurs in a highly regulated 
temporal manner. Three classes of genes have1been defined 
based on the timing and requirements of their expression. 
Alpha genes are expressed earliest in infection (4-6 h for 
HSV, 12-24 h for HCMV) without any requirement for prior viral 
protein synthesis. Beta gene expression requires prior alpha 
protein synthesis but not replication of viral DNA. The beta 
proteins include regulatory proteins and enzymes required for 
replication of viral DNA (e.g. viral DNA polymerase). 
Expression of the third class of genes, gamma genes, is 
dependent on replication of viral DNA. Most viral structural 
proteins are gamma proteins. 
After the viral genome has been replicated and structural 
5 
proteins have been synthesized, nucleocapsids are assembled 
in the nucleus and bud through the inner nuclear membrane into 
the perinuclear space. Virions are then transported through 
the endoplasmic reticulum and Golgi apparatus to the cell 
surface where they are released. 
Epidemiology of HSV and HCMV. Primary HSV-1 infection 
typically occurs in childhood following contact with a virus 
positive individual. Initial HSV-2 infection occurs either 
at delivery through contact with the birth canal of an 
infected mother, or later in life as a sexually transmitted 
disease. Primary infections with both serotypes can be 
asymptomatic. When apparent, the infection is self-limiting. 
However, in immunocompromised individuals and newborns, HSV 
infection can spread from the primary site of infection to 
other parts of the body and is frequently fatal. The clinical 
manifestations and course of HSV disease depend on the 
anatomical site of infection, the age and immune status of the 
host, and the antigenic type of the virus. 
After primary infection, HSV travels to the regional 
sensory ganglia that innervates the site of inoculation. 
Although the mechanism is not fully understood, the most 
rational hypothesis is retrograde axonal spread or transport 
of HSV along microtubules by movement of membrane bound 
organelles. 
within the 
The virus permanently maintains a latent state 
ganglia although infectious virus cannot be 
detected. Several latency-associated transcripts (LATs) have 
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been detected by in situ hybridization (112). Experiments 
performed using mutants containing deletions within the LAT 
gene suggest that LATs are not essential for establishment or 
maintenance of latency ( 67, 115) , but may play a role in 
reactivation of the virus (9). Once reactivated, the virus 
migrates back to the site of the primary infection and begins 
the replication process. The clinical manifestations of these 
periodic reactivations can be life-threatening for individuals 
who are immunosuppressed (40,42,75,102). 
Acquisition of HCMV can occur through natural routes or 
through transfusion and transplantation (1,44). In the first 
case, acquisition appears to require close or intimate contact 
with persons who are excreting HCMV in their urine, saliva, 
semen, tears, or other secretions (113). Development of HCMV 
disease after transfusion and transplantation can be the 
result of a natural infection, a donor-induced infection, or 
reactivation of a latent infection. HCMV infection in heal thy 
individuals is usually asymptomatic or results in a self-
limi ted infectious mononucleosis-like syndrome. However, 
severe and life-threatening HCMV disease may develop in 
immunocompromised patients such as transplant recipients or 
AIDS patients (1,3,21,44,122). In these patients, the 
clinical manifestations include pneumonia, hepatitis, GI 
involvement, and chorioretinitis (1). 
HCMV is the most frequent viral agent causing congenital 
malformations (1,3,44,127). Neonatal infection occurs as the 
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result of either primary infection in the mother or 
reactivation or reinfection followed by passage of the virus 
across the placenta ( 113) . Clinically apparent HCMV infection 
can be demonstrated in about 1% of newborns, and about 10-15% 
of the infected children suffer either from immediate symptoms 
or late sequelae such as mental retardation, chorioretinitis, 
microencephaly, and hearing loss. 
The site of latency of HCMV has not yet been determined. 
HCMV latency may be associated with a nonproductive cell that 
permits only limited viral gene expression (116). 
Polymorphonuclear and mononuclear leukocytes can be infected 
in vitro resulting, however, in an abortive infection (100). 
Limited viral expression occurs in these cells since HCMV DNA 
and RNA can be demonstrated in these cell types by in situ 
hybridization (27,100,104). Data also suggest that latent 
HCMV is transferred from donor to recipient during blood 
transfusion (44). Although factors controlling HCMV latency 
and reactivation are not understood, immunosuppression appears 
to promote reactivation (44). 
Both HSV and HCMV gene products have been shown to 
transactivate the HIV-1 long terminal repeat (LTR) in vitro, 
suggesting that they may play a role as cofactors in the 
development of AIDS (4,98). In addition, in vitro studies 
suggest that there may be bidirectional potentiation between 
HCMV and HIV (60,107). In vivo evidence exists for 
coinfection of HCMV and HIV-1 in cells from the white matter 
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of AIDS patients (89). Potentially, herpesvirus gene products 
may act through the LTR to increase initiation of HIV-1 
transcripts. 
Recently, Lerner-Tung et al. (74) demonstrated formation 
of guinea pig cytomegalovirus (GPCMV) and guinea pig 
retrovirus (GPRTV) pseudotypes in cultured guinea pig cells. 
Formation of GPRTV pseudotypes which now express GPCMV 
antigens on their envelopes would extend the host cell range 
of the retrovirus. These interactions may have serious 
implications for human patients with retroviral infection and 
a supervening HCMV infection. 
Normal HSV- and HCMV-specific cytotoxic T lymphocyte 
response, normal levels of natural killer cells, and normal 
levels of antibody-dependent cellular cytotoxicity appear to 
play an important role in prevention of HSV and HCMV diseases 
(24,101). In contrast, HSV and HCMV infections in patients 
with primary B-cell disorders such as agammaglobulinemia are 
usually not severe. 
Oncoqenicity. Both HSV and HCMV can transform cells in 
vitro and induce malignant disease in animals. Small segments 
of the HSV and HCMV genomes were able to transform NIH 3T3 
cells ( 48, 88) . Epidemiologic evidence suggests that HSV 
infection may play a role in cervical (87) and vulvar (69) 
carcinomas. The presence of HCMV nucleic acid in human tumors 
is difficult to interpret because HCMV can infect these organs 
latently in a high percentage of individuals. 
9 
studies have shown that HCMV infection induces cell DNA 
synthesis and cell proliferation ( 52) . Colberg-Poley and 
santomenna (19) showed that permissive infection of HFF with 
HCMV increases the abundance of transcripts from selected 
growth-related HFF genes. HCMV infection also increases the 
level of c-fos, c-jun, and c-myc RNA within infected cells 
( 10) . These proto-oncogenes play a pivotal role in regulation 
of cell proliferation. Increased cell proliferation mediated 
by HCMV infection through increased RNA levels of genes which 
regulate cell growth may be the first step in HCMV 
oncogenesis. 
Laboratory diagnosis. The primary method of detection 
of HSV and HCMV in clinical samples is by conventional cell 
culture. However, demonstration of HCMV in cell culture can 
take several weeks due to the increased replication time and 
cell-associated nature of the virus. Paya et al. (95) 
developed a rapid and reliable shell vial assay which is 
routinely used in conjunction with conventional tube culture. 
Patient samples are inoculated into shell vials containing HFF 
seeded glass covers lips. The vials are centrifuged to promote 
adherence and absorption of the virus. After 24 to 48 h 
incubation, the monolayers are stained with an indirect 
fluorescent antibody technique using a HCMV-specif ic 
monoclonal antibody. Preliminary positive results can be 
reported as early as 24 h post inoculation. 
Serological and histological tests can aid- in the 
10 
detection of HCMV disease. Demonstration of a four-fold rise 
in titer of HCMV-specific antibodies is indicative of active 
disease. However, acute and convalescent sera are required 
and results may not be reliable in immunosuppressed patients. 
Histology performed on biopsy samples may also reveal the 
presence of characteristic herpesvirus inclusion bodies in 
infected cells. 
several additional techniques have been described for 
rapid detection of HCMV infection. Radiolabeled and non-
radiolabeled HCMV probes have been developed for in situ 
hybridization or Southern blot hybridization of patients 
samples {16,77,85,111). However, these techniques are labor-
intensive and are not as sensitive as the combined shell vial 
and immunofluorescence method. Demmler et al. (30) and Olive 
et al. (93) reported polymerase chain reaction {PCR) 
amplification of HCMV DNA in urine specimens. Primers were 
used to amplify the major immediate-early and late antigen 
genes of HCMV. Flow cytometry has been used to detect HCMV 
early nuclear antigen in infected fibroblasts {38). Positive 
results were obtained earlier than with the shell vial assay 
or conventional culture. 
strategy of anti-herpesvirus therapy. The first class 
of anti-herpesvirus agents are the viral DNA polymerase 
inhibitors. HSV encodes a DNA polymerase enzyme characterized 
by 1) salt-stimulated polymerase activity, 2) 3 '-5' 
exonuclease activity, 3) a deoxynucleotide (dNTP) binding 
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site, 4) a pyrophosphate (PPi) binding site, 5) a DNA binding 
site, and 6) aphidicolin and phosphonoacetic acid (PAA) 
sensitivity (31). Although the HCMV polymerase has not been 
studied as extensively, it also possesses polymerase activity, 
3 • -5 • exonuclease activity, and aphidicolin and PAA 
sensitivity (58,63,71). The genetic location of both enzymes 
has been mapped to the long unique region of each genome and 
the nucleotide sequences have been deduced (28, 58, 71, 96). 
Both polymerases show areas of considerable amino acid 
homology to the DNA polymerase protein of other another herpes 
virus, Epstein-Barr virus, as well as human DNA polymerase a, 
yeast DNA polymerase I, and several animal and bacterial 
polymerase enzymes (49,58,71,72,73,124,126). Recent 
successful cloning and expression of the HSV DNA polymerase 
(31,55,56) will allow further characterization of the enzyme. 
Unfortunately, attempts at expressing the HCMV DNA polymerase 
in expression vectors have been unsuccessful. 
The second class of anti-herpesvirus agents are the 
nucleoside analogs including acyclovir (ACV) and ganciclovir 
(GCV). These agents are substrates for the virus-encoded 
thymidine kinase (TK). Monophosphorylation of the nucleoside 
analogs by the viral TK is the essential first step in their 
activation. Following conversion of the mono-phosphorylated 
nucleoside analogs to their triphosphate forms by host 
cellular kinases, the latter become preferential substrates 
for the herpesvirus-specific DNA polymerases. Incorporation 
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of the triphosphorylated analogs into viral DNA results in 
disruption of further DNA polymerase activity. 
The HSV TK gene has been mapped to the long unique region 
of the genome (84) and has been cloned (51) and sequenced 
(70). HCMV does not encode a virus-specific thymidine kinase 
which can be separated from host cell activity (41, 128). 
However, studies have shown that HCMV-infected cells are 
capable of monophosphorylating GCV ( 8) • Conversely., two GCV-
resistant mutants of HCMV lack this activity (7,76). Whether 
the virus encodes some type of GCV-specific kinase activity 
or whether it stimulates the activity of a cellular enzyme 
which is responsible for GCV-monophosphorylation has yet to 
be determined. 
Viral resistance to the nucleoside analogs can occur 
through several mechanisms. Mutations in the HSV TK gene can 
induce truncated inactive TK polypeptides.following premature 
termination at a stop codon ( 42) . These TK- HSV mutants 
therefore lack the ability to monophosphorylate ACV. A second 
class of ACV-resistant HSV induced a mutated TK which retained 
the ability to phosphorylate thymidine (42). The mutant viral 
TK was found to have a changed substrate specificity 
preventing monophosphorylation of the drug and resulting in 
resistance to one or more nucleoside analogs. Also, mutations 
in the viral DNA polymerase may result in an enzyme which no 
longer recognizes the triphosphorylated analog. This class 
of mutants, however, remain susceptible to the DNA polymerase 
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inhibitors. 
Resistance to the DNA polymerase inhibitors including 
phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) is 
mediated specifically through mutations in the viral DNA 
polymerase gene. Mutants of this class show cross-resistance 
to the nucleoside analogs. These mutants display wild-type 
levels of phosphorylation of the nucleoside analogs. However, 
the mutation in the DNA polymerase enzyme prevents 
incorporation of the nucleoside triphosphate. 
Anti-herpesvirus agents. ACV, an acyclic analogue of 
2•-deoxyguanosine (Figure 1), has been extensively reviewed 
in the literature (36,59,62,99,123). ACV has potent anti-HSV 
activity in vitro and is sufficiently safe for human use. HSV 
infection induces a novel viral TK activity that is essential 
for the phosphorylation of ACV to ACV-monophosphate, the first 
step in the selective activation of ACV. Normal cellular 
enzymes do not monophosphorylate ACV to any significant 
degree. ACV-monophosphate is further phosphorylated to the 
diphosphate and triphosphate forms by cellular kinases. Once 
incorporated into the growing viral DNA chain, ACV-
triphosphate prevents further chain elongation because of the 
absence of a 3'-hydroxyl group (Figure 1). Alsoi ACV cannot 
be excised from the DNA because the terminated chain is not 
a suitable substrate for the viral DNA polymerase-associated 
3'-exonuclease activity (36). Therefore, the enzyme complex 
is inactivated and is no longer available to catalyze any 
14 
Figure 1. Structures of acyclovir and ganciclovir. 
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further reactions (36). ACV-triphosphate is a more potent 
inhibitor of HSV DNA polymerase than of cellular DNA 
polymerase and therefore induces very little host cell 
cytotoxicity (36). ACV has very weak in vitro activity 
against HCMV (20,46,123) possibly due to the fact that HCMV 
infection induces only modest levels of ACV-triphosphate (8). 
GCV, a recently developed acyclic analog of guanosine 
(Figure 1), is a potent inhibitor of HSV and HCMV replication 
(8,43,46,79,83,108). Like ACV, inhibition of viral 
replication by GCV is due to the selective inhibition of the 
HCMV DNA polymerase by GCV-triphosphate, with the host cell 
polymerase being much less sensitive (8,46,79). As mentioned 
above, HCMV does not encode a virus-specific TK. GCV 
anabolism studies have shown that levels of phosphorylated 
products of GCV increase in HCMV infected cells (8). 
Therefore, GCV must be monophosphorylated by a virus-encoded 
or virus-induced cellular enzyme. Cellular kinases 
phosphorylate the drug to the active triphosphate form. 
Although similar in structure to ACV, GCV possesses a 3 '-
hydroxyl group allowing incorporation of the active form into 
the growing viral DNA chain (Figure 1). GCV-triphosphate is 
probably not a strict chain terminator, but may act by 
disrupting the conformation and integrity of the DNA helix 
( 59) • GCV is currently the only FDA-approved drug for the 
treatment of AIDS-related HCMV retinitis. However, GCV has 
a narrow therapeutic-toxic ratio and often causes reversible 
17 
neutropenia (59). 
AraA and AraT are nucleoside analogs with some activity 
against all members of the human herpesvirus group, but less 
activity against HCMV or EBV than against HSV or varicella 
zoster virus {59). Both inhibit viral DNA synthesis at 
concentrations below those required to inhibit host-cell DNA 
synthesis. In contrast to ACV and GCV, AraA and AraT are 
first monophosphorylated by cellular enzymes. . They are 
further phosphorylated to their active triphosphate forms by 
cellular kinases. Therefore, since they are not dependent on 
the activity of the viral TK, they are active against TK-
mutants of HSV. 
HPMPA ((~)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-
adenine) and HPCMC {{~)-l-{3-hydroxy-2-phosphonylmethoxy­
propyl)cytosine are phosphonate derivatives of acyclic 
analogues of adenosine and cytosine, respectively {Figure 2). 
In vitro, both show selectivity against a broad spectrum of 
DNA viruses including HSV, HCMV, and EBV {29,90,105,109). 
HPMPA and HPMPC do not require phosphorylation by a viral-
encoded kinase to express antiviral activity (105), and, 
therefore, are effective against TK- strains of HSV (29,90). 
These agents are diphosphorylated by cellular enzymes and the 
diphosphoryl derivatives interfere with the viral DNA 
polymerase reaction. 
PFA and PAA (Figure 3) are pyrophosphate (PPi) analogs 
which have significant anti-HSV and anti-HCMV activity in 
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Figure 2. Structure of HPMPC and HPMPA. 
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Figure 3. Structure of PAA and PFA. 
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vitro and in vivo (59,62,123). studies have shown that PFA 
blocks the PPi binding site of the viral DNA polymerase 
preventing cleavage of pyrophosphate from the deoxynucleotide 
triphosphates (dNTPs) (17,91). Formation of the PFA-enzyme 
complex prevents release from, or translocation along, the 
template primer. Further studies suggest that PFA and 
pyrophosphate bind to distinct sites within the proposed PPi 
binding site (50) on the enzyme. PFA selectively inhibits 
viral polymerases at concentrations which do not affect host-
cell polymerases. Ongoing clinical studies with PFA have 
shown that PFA may be effective and safe in the treatment of 
AIDS-related HCMV retinitis (17). 
Aphidicolin, a fungal tetracyclic diterpenoid, is a 
specific inhibitor of the DNA a polymerase family. This agent 
also has potent anti-herpesvirus activity (53,57). In vitro, 
its inhibitory action stems from its presumed interaction with 
the nucleotide-binding domain. Several aphidicolin-resistant 
vaccinia virus mutants encode DNA polymerase enzymes which 
contain a substituted amino acid within a conserved domain 
thought to be involved in nucleotide binding (118). The 
clinical application of aphidicolin is limited by its 
detrimental effect on cellular DNA synthesis (53) and 
therefore may be more useful for studying the in vitro 
interactions between the viral DNA polymerase and dNTPs. 
The activity of anti-herpes group drugs is determined 
using the plaque reduction assay {PRA; 125). In thfs assay, 
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cell monolayers are inoculated at a certain multiplicity of 
infection (MOI) to yield a countable number of plaques. The 
monolayers are then incubated in various dilutions of the 
antiviral agent. The IC50 or ED50 is defined as the 
concentration of drug which results in a 50% decrease in the 
number of plaques as compared to the control wells. Antiviral 
susceptibility testing of HSV using the PRA is rapid and 
reproducible. However, due to the slow growing .nature of 
HCMV, antiviral susceptibility testing of HCMV using the PRA 
can take up to two weeks per assay. The need exists for a 
more rapid testing procedure for HCMV. 
Resistance to anti viral drugs. The numerous drug-
resistant mutants of HSV reported are either laboratory-
deri ved mutants or clinically isolated strains. All provide 
excellent models for the study of drug-enzyme interactions. 
Of most concern are the increasing numbers of drug-resistant 
HSV-1 and HSV-2 being isolated from immunocompromised patients 
(6,13,23,40,75,102). ACV resistance typically becomes 
apparent during or after a period of antiviral therapy. The 
infection may be resolved after administration of PFA if the 
ACV-resistant virus is a TK- mutant (13,40,75,102). However, 
treatment with viral DNA polymerase inhibitors may be 
ineffective if the mutation lies in the viral DNA polymerase 
gene (23). 
Sequence analysis of the TK and DNA polymerase genes of 
HSV drug-resistant mutants has suggested that point mutations 
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in these genes may be responsible for drug resistance 
(l2, 71,120). Marcy et al. (80) successfully constructed drug-
resistant recombinant HSV-1 which contained point mutations 
in the viral DNA polymerase gene. Gibbs et al. (71) mapped 
the location of nine HSV DNA polymerase mutants. They 
proposed that a dNTP binding site and a PPi binding site lie 
in the carboxyl terminal portion of the HSV DNA polymerase 
protein. This area shows significant homology to other human 
DNA a polymerase-like proteins. 
To date, there have been only two reports describing 
resistance to GCV in clinical isolates of HCMV. In order to 
determine the prevalence of resistance of HCMV to GCV in 
patients with AIDS, Drew et al. (33) performed serial cultures 
of patients receiving GCV for HCMV retinitis. Of 31 isolates 
tested prior to therapy, all were GCV-sensitive. Thirteen 
patients were cul ture-posi ti ve after 3 or more months of 
treatment. Five of these isolates were GCV-resistant (ED50 >12 
uM). Three other Gcv~resistant clinical isolates from 
immunosuppressed patients have been described (39). However, 
the mechanism of resistance of these GCV-resistant isolates 
was not determined in either study. 
Only, three laboratory-derived drug-resistant HCMV 
isolates have been reported. Two GCV-resistant mutants were 
isolated by passage of wild-type AD169 in increasing 
concentrations of GCV (7,76). Analysis of phosphorylation 
products of GCV in virus-infected cells showed the isolates 
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to be deficient in kinase activity. Since the isolates were 
not cross-resistant to the viral DNA polymerase inhibitors, 
this suggested that the mutation responsible for drug 
resistance was in the gene encoding kinase activity. D 'Aquila 
and summers (28) isolated PAA-resistant HCMV mutants by 
passage of wild-type AD169 in increasing concentrations of 
PAA. These mutants had PAA-resistant DNA polymerase activity 
in vitro suggesting that mutations responsible for PAA 
resistance were in the HCMV DNA polymerase gene. 
Prevention. Strategies for vaccine development have 
centered on the use of live attenuated viral vaccines and 
viral subunit vaccines ( 2 5, 54) . However, concern exists about 
the long-term safety of any attenuated live virus. Mutations 
restoring the pathogenicity of the virus could lead to 
disease. Also, the transforming properties of both HSV and 
HCMV sequences may be of concern. Active research continues 
in the development of safe subunit vaccines. HCMV sero-
negative transplant recipient patients and HCMV sero-negative 
women of child-bearing age would greatly benefit from a 
preventative vaccine (113). 
strain variation may play an important role in HCMV 
vaccine design. James et al. {66) demonstrated antigenic 
variation among HCMV isolates using monoclonal antibodies and 
an indirect ELISA. Restriction endonuclease patterns of 
clinical isolates also demonstrate strain variation 
( 15, 34, 122) and that patients may shed several different 
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strains of HCMV simultaneously (22,110). Therefore, effective 
vaccine design should be targeted to conserved areas of the 
virus. 
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MATERIALS AND METHODS 
Tissue culture cells. Low passage human foreskin 
fibroblasts (HFF) were purchased from Bartels (Bellevue, WA). 
confluent monolayers of HFF in 150 cm2 tissue culture flasks 
were passaged 1:2 and grown to confluency in growth medium 
(Eagle's minimal essential medium (EMEM) containing 
amphotericin B (2. 5 µg/ml) and gentamicin ( 50 µg/ml) and 
supplemented with 2 mM L-glutamine, 5% fetal calf serum (FCS) 
and 5% NuSerum (92; Collaborative Research, Inc., Lexington, 
MA)). The cells were then held on maintenance medium (EMEM 
containing amphotericin B (2. 5 µg/ml) and gentamicin (50 
µg/ml) and supplemented with 2 mM L-glutamine and 1% FCS). 
HFF cells greater than passage 11 were discarded. 
Monolayers of HFF in 24-well tissue culture treated 
plates were prepared by harvesting cells from a confluent 150 
cm2 flask, resuspending the cells in 100 ml of growth medium, 
and adding 1 ml of cell suspension to each well of 4 plates. 
The plates were incubated at 37°C in 4% co2 • Monolayers of HFF 
in 96-well tissue culture treated plates were prepared in a 
similar manner with the following modifications. Cells were 
resuspended in 75 ml of growth medium and the 60 inner wells 
of 6 plates were seeded with 0.2 ml of cell suspension. All 
outer wells were filled with 0.2 ml of sterile water. 
Monolayers of HFF in 100 mm tissue culture dishes were 
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prepared by harvesting the cells from a confluent 150 cm2 
flask, resuspending the cells in 40 ml of growth medium, and 
adding 10 ml of cell suspension to each of 4 dishes. 
African green monkey kidney cells (Vero cells) were 
propagated and maintained in a similar manner. For 
propagation, Vero cells were split 1:5. Preparation of 
multiwell plates and tissue culture dishes was identical to 
that of HFF cells except that a confluent 75 cm2 .flask of 
Vero cells was used to seed 4 24-well plates, 6 96-well 
plates, or 4 100 mm dishes. 
Viruses. HCMV strain AD169 (ATCC VR-538) was used 
throughout this study. Medium from a confluent monolayer of 
HFF cells in a 150 cm2 flask was removed and replaced with 3 
ml of stock virus diluted in maintenance medium (MOI = 0.01-
0.001). After a 2 h absorption period at 37°C, the inoculum 
was replaced with maintenance medium. At approximately 10 % 
CPE, the medium was replaced with fresh maintenance medium. 
At 3 days past 100% CPE, the culture fluid was removed, 
dimethyl sulfoxide (DMSO; Kodak, Rochester, NY) and FCS were 
added to a final concentration of 10% and aliquots were frozen 
at -7o0 c. 
HCMV isolated from heart, bone marrow,. or kidney 
transplant patients at LUMC were obtained from the clinical 
microbiology laboratory. The initial isolation of the virus 
was done in tubes of HFF. Most commonly, the monolayers 
showed only one to a few areas of CPE. The medium from these 
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tubes was aspirated, the monolayers were scraped with a 
sterile plastic 1 ml pipet, and the cells were resuspended in 
o.4 ml of maintenance medium. Two low passage tubes of HFF 
(Bartels, Bellevue, WA) were inoculated with 0.2 ml of cell 
suspension and incubated for 2 h at 37°C to allow viral 
adherence. The tubes were then fed with 2 ml maintenance 
medium containing 1% FCS and incubated at 37°C for five weeks. 
The medium was changed weekly. If the CPE did not reach 100% 
after 5 weeks, the cells were again passed in a similar 
manner. At 100% CPE, the fluid was diluted 1:100 in 
maintenance medium and 0.2 ml of ~he diluted virus suspension 
was used to inoculate new HFF tubes. When the CPE in the 
tubes reached 100% CPE, the fluid was harvested, FCS and DMSO 
were added to 10%, and 0.4 ml aliquots were frozen at -7o0c. 
Wild-type HSV-1 strain KOS and HSV-2 ATCC VR-734 stock 
virus was prepared by inoculating confluent monolayers of Vero 
cells in 75 cm2 flasks with 2 ml of virus in maintenance 
medium at an MOI of 0.005. Flasks were incubated at 37°C for 
1 h. The inoculum was then replaced with 15 ml of maintenance 
medium. The flasks were incubated at 37°C for 3-4 days until 
100% CPE was observed. The culture fluid was collected, DMSO 
and FCS were added to 10%, and 0.5 ml aliquots of the fluid 
were stored at -10°c. 
Anti viral agents. Acyclovir (ACV) was a gift from 
Burroughs-Wellcome, Research Triangle Park, NC. Ganciclovir 
(GCV) was a gift from Burroughs-Wellcome, Research Triangle 
park, NC, and Syntex, Palo Alto, CA. 
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Phosphonof ormic acid 
(PFA), phosphonoacetic acid (PAA) , adenine 9-B-D-
arabinofuranoside (AraA), thymine-1-D-arabinofuranoside 
(AraT), and aphidicolin {Aph) were obtained from Sigma 
chemical Co., St. Louis, MO. (~)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine (HPMPC) and (S)-9-(3-hydroxy-
2-phosphonylmethoxypropyl)adenine (HPMPA) were gifts from 
Bristol-Myers Squibb (Wallingford, CT). All antiviral agents 
were resuspended in distilled water and filter sterilized {0.2 
µm) . stocks were stored at -20°c. 
Plaque dilution assay. The plaque dilution assay used 
in this study was a modification of the method of Wentworth 
and French {125). For the HCMV plaque dilution assay, 10-'fold 
dilutions of stock virus were made in maintenance medium. The 
medium from each well of monolayers of HFF in 24-well tissue 
culture plates was aspirated and replaced with 0.1 ml of the 
appropriate virus dilution. Each dilution was run in 
quadruplicate. After a 2 h absorption at 37°C in 5% co2 , viral 
inoculum was removed and replaced with 1 ml of maintenance 
medium containing o. 3% agarose. Plates were incubated at 37°C 
in 5% co2 for 1 week. A second overlay of maintenance medium 
containing 0.3% agarose was added to each well and plates were 
incubated an additional week. Plaques were counted 
microscopically and the virus titer was determined. 
The HSV plaque dilution assay was identical to the HCMV 
plaque assay with the following modifications. Confluent Vero 
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cell monolayers in 24-well tissue culture plates were 
inoculated with dilutions of stock HSV. After a 1 h 
absorption at 37°C in 5% C02 , viral inoculum was removed and 
replaced with 1 ml of maintenance medium containing 15% 
methylcellulose (Sigma Chemical Co., St. Louis, MO). The 
plates were incubated at 37°C in 5% co2 for 2 to 4 days post-
inoculation until sufficient plaque formation was visible. 
The cells were fixed by replacing the medium wi.th 0.5 ml 
methanol and incubating the plates for 3 min at room 
temperature. The methanol was removed and the plates were 
allowed to dry at room temperature. The monolayers were 
stained with 0.5 ml of 1% methylene blue for 10 min at room 
temperature. The dye was aspirated and the plates were dried 
prior to microscopic examination. 
Percent survival assay. Monolayers of HFF or Vero cells 
in 24-well cell culture plates were inoculated with virus as 
in the plaque dilution assay. After virus adherence, 
monolayers were overlaid with the appropriate medium with or 
without anti viral compound. Plates were incubated until 
substantial plaque formation was observed in the control wells 
without antiviral drug. The percent survival is defined as 
(titer of virus in the presence of drug)/(titer of virus in 
the absence of drug) X 100. 
Plaque reduction assay. The plaque reduction assay was 
performed as in the plaque dilution assay with the following 
modifications. HFF or Vero cell monolayers were inoculated 
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with a virus dilution sufficient to yield approximately 20 
plaques per well. After the virus adherence, monolayers were 
overlaid with the appropriate medium with or without dilutions 
of the antiviral compound. Plates were incubated until 
substantial plaque formation was observed in the control wells 
without drug. The IC50 was defined as the concentration of 
drug which resulted in a 50% or greater decrease in virus 
titer as compared to the no drug control. 
Viral DNA isolation. For extracellular virus DNA 
isolation, stock virus was grown as described above in 150 
cm2 tissue· culture flasks or 490 cm2 , 850 cm2 , or 1700 cm2 
tissue culture roller bottles. Culture fluid was transferred 
to 250 ml centrifuge bottles and centrifuged in a Sorvall GSA 
rotor at 5, 000 x g for 10 min at 4°C. The supernatant was 
transferred to sterile 40 ml Oak Ridge tubes and centrifuged 
at 25,000 x g in a Sorvall SS34 rotor at 4°C for 90 min. The 
supernatants were decanted and the pellets were resuspended 
in 0.5 ml DNA buffer (0.4 M sodium chloride (NaCl), 0.5 mM 
Tris-HCl pH 8, 0.1 M ethylenediaminetetraacetic acid (EDTA) 
containing 500 ug/ml heat-treated RNase, 1.0% sodium dodecyl 
sulfate (SOS) and 0.5% Sarkosyl. The tube was then incubated 
for 2 h at 37°C. After addition of pronase (1 mg/ml), the 
tube was incubated overnight at 37°C. 
The fluid was transferred to 1. 5 ml microcentrifuge 
tubes. The DNA was extracted once by the addition of an equal 
volume of phenol saturated with Tris-HCl pH 8.0 followed by 
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centrifugation for 5 min at 12,000 x g. The upper aqueous 
layer was transferred to a new microcentrifuge tube and 
extracted with and equal volume of chloroform:isoamyl alcohol 
(24:1). The upper aqueous layer was again transferred to a 
new microcentrifuge tube. The DNA was precipitated by the 
addition of 2 volumes 95% ethanol (EtOH) and incubation at -
20°c overnight. The DNA was pelleted by centrifugation at 
12,000 x g for 10 min at 4°C. The DNA pel·lets were 
resuspended in 20 ul TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). 
DNA quanti tat ion was determined by agarose gel electrophoresis 
using known DNA standards. 
Cell-associated viral DNA was isolated using a modified 
Hirt extraction (35). Stock virus was grown in 150 cm2 flasks 
as described above. The culture fluid was removed and 
extracellular virus was isolated from the fluid as described 
above. The monolayer was washed with 5 ml phosphate buffered 
saline (PBS). One milliliter of lysis solution (0.01 M Tris 
pH 8.0, 10 mM EDTA, 0.5% SOS) was added per flask and the 
flasks was incubated at 37°C for 15 min. The solutions were 
pooled and transferred to 15 ml Corex tubes. After addition 
of 5 M NaCl to a final concentration of 1 M, the tubes were 
incubated at 4°C overnight. The tubes were spun at 25,000 x 
g at 4°C in the SS34 rotor. The supernatant was transferred 
to a new Corex tube and extracted with an equal volume of 
phenol saturated with 10 mM Tris-HCl pH 8.0. The tubes were 
spun at 8,000 x g for 10 min. The upper aqueous layers were 
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transferred to new Corex tubes and extracted with an equal 
volume of chloroform: isoamyl alcohol (24: 1) • Again, the upper 
aqueous layer was transferred to a new Corex tube, two volumes 
of 95% EtOH were added, and the DNA was precipitated at -20°c 
overnight. The DNA was collected by centrifugation for 30 
min at 25,000 x g at 4°C. The fluid was decanted and the 
pellets were dried. The DNA was resuspended in 1 ml of TE. 
DNA concentration was determined as above. 
Cell-associated viral DNA was also isolated using an 
alternate method. Stock virus was grown as described above. 
The culture supernatant was centrifuged at 5, 000 x g as 
described above for extracellular virus isolation. However, 
the· cell pellet was saved. Any remaining adherent cells in 
the flasks were harvested by trypsinization and added to the 
tubes containing the initial cell pellets. Cells were 
pelleted at 5,000 x g. The fluid was removed and the cells 
were resuspended in 10 ml of lysis solution (1% sos, 500 ug/ml 
RNase A, 0.45% sodium deoxycholate, in TE), transferred to 40 
ml Oak Ridge tubes, and incubated at 37°C for 2 h. After 
addition of 0.1 ml proteinase K (20 mg/ml), the tubes were 
incubated overnight at 37°C. The volume of each tube was 
adjusted to 25 ml with TE and 32. 5 g of cesium chloride (CsCl) 
was added and mixed. The DNA solution was centrifuged in the 
Vti 50 rotor at 40,000 rpm at room temperature for 20 h in a 
Beckman ultracentrifuge. Fractions (0.5 ml) were collected 
in microcentrifuge tubes. The DNA in fractions with a 
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refractive index of 1. 4007-1. 4030 was precipitated by the 
addition of 1/10 volume of 3 M sodium acetate pH 5.2 and 2 
volumes of 95% EtOH. After overnight incubation at -20°c, 
tubes were centrifuged at 12,000 x g for 10 min. The fluid 
was decanted and the DNA pellets were dried. DNA 
concentration was determined as before. 
ELISA for HCMV late nuclear antigen. Confluent 
monolayers of HFF in 96-well tissue culture treated plates 
were prepared as previously described. The configuration of 
the plates consisted of six uninfected cell control wells, 
six virus control wells, and six wells per drug concentration 
(eight concentrations per plate). The growth medium was 
removed from the wells and 50 µl of maintenance medium was 
added to the cell control wells and 50 µl virus inoculum was 
added to the remaining wells. The virus was allowed to adsorb 
for 2 h at 37°C and 5% co2• The viral suspension was removed 
and 0.2 ml of maintenance medium was added to the cell control 
and virus control wells. Increasing concentrations of the 
antiviral agent diluted in maintenance medium was added to the 
remaining wells. The plates were then incubated at 37°c in 5% 
co2 • 
At various times, plates were removed and the medium was 
aspirated. One hundred microliters of blocking solution (0.5% 
bovine serum albumin (BSA) in PBS) was added to each well and 
the plates were incubated at room temperature for 30 min. 
Blocking solution was aspirated and the cells were fixed by 
36 
adding 0.1 ml ethanol:acetone (95:5) per well and incubating 
the plates at -20°C for 30 min. Each well was washed 5 times 
with 0.2 ml of wash solution (PBS containing 0.5% BSA and 
o.o5% Tween 20). One hundred microliters of monoclonal anti-
CMV late nuclear antigen (DuPont, Wilmington, DE) diluted 
1:200 in PBS containing 10% goat serum, 1% FCS, and 0.05% 
Tween 20 was added to each well and the plates were incubated 
at 37°C for 1 h. The primary antibody solution was. aspirated 
and the cells were washed as before. One hundred microliters 
of horseradish peroxidase conjugated goat anti-mouse IgG (Bio-
Rad Laboratories, Richmond, CA) diluted 1:500 in PBS 
containing 10% goat serum and O. 05% Tween 20 were added to the 
wells · and plates were incubated at 37°C for 2 h. The 
secondary antibody solution was aspirated, the cells were 
washed as before, and o. 2 ml of substrate solution ( 2, 2 ' -
azinobis(J-ethylbenzthiazoline sulfonic acid) (AEBS; Sigma, 
St. Louis, MO; 1 mg/ml), 0.01% hydrogen peroxide in phosphate-
citrate buffer pH 4.8) was added to each well. The plates 
were incubated at room temperature for approximately 15 to 20 
min. The plates were then mixed (Shaking Apparatus, Arthur 
H. Thomas Co., Philadelphia, PA) and the optical density (OD) 
of each well were read against a distilled water blank using 
a Dynatech MR580 Microelisa Auto Reader set at a wavelength 
of 450 nm. In some cases, TMBlue (3,3',5,5'-tetramethyl-
benzidine) substrate solution (Transgenic Sciences, Inc., 
Worcester, MA) was used for detection with the following 
modifications. 
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The primary antibody was diluted a final 
concentration of 1:600, and the OD~0 was determined after 5-
lO min incubation at room temperature. In comparison to AEBS, 
TMBlue required no preparation and is non-mutagenic. In 
addition, the color change of this substrate occurred faster 
than AEBS. 
The average OD of the six identical wells for each drug 
concentration was calculated and the change in OD as compared 
to the uninfected cell control was then calculated. The 
percent change in OD was calculated as follows: (average 
sample OD)/{aVerage virus control OD - average cell control 
OD) x 100. The inhibitory concentration {IC50 ) was defined 
as the concentration of antiviral agent which produced a 50% 
reduction in the OD of the colored substrate solution. 
ELISA for HSV-2 antigen. The in situ ELISA for the 
quanti tat ion of HSV-2 antigen was performed as previously 
described for HCMV with the following modifications. 
Microtiter plates were seeded with Vero cells. HSV-2 ATCC 
VR-734 was used as the control virus. The virus was allowed 
to adhere for 1 h. The plates were incubated 2 to 3 days 
until substantial plaque formation was observed. The primary 
antibody was HSV-II(IgGl) Cell Line 1 (DuPont Company, 
Wilmington, DE) used at a final dilution of 1:200. 
HPLC analysis of GCV anabolism in HCMV-infected HFF. 
HFF were seeded into 75 cm2 tissue culture flasks and 
incubated until confluent. The flasks were inoculated with 
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2.5 ml of HCMV diluted in maintenance medium at an MOI of 1. 
virus was allowed to absorb at 37°C for 2 h. The inoculum 
was removed and replaced with 15 ml of maintenance medium. 
After 3 days incubation at 37°c, the medium in each flask was 
replaced with 7.5 ml of maintenance medium containing 235 µl 
3H-GCV (approximately 1 x 107 cpm; a gift from Syntex, Palo 
Alto, CA) and unlabelled GCV (25 µM final concentration) • To 
ensure the sterility of the labelled medium, the ~H-GCV was 
first added to 10 ml of medium. The solution containing the 
radiolabelled GCV was then filter sterilized (0.45 µm filter) 
and brought to volume with the remaining medium and GCV. The 
flasks were incubated an additional 24 h at 37°C. 
The medium was removed from the flasks and the cells were 
treated with 0.5 ml of 0.5% trypsin for 10 min at 37°C. The 
cells were resuspended in 3 ml of growth medium and 
transferred to a 15 ml conical tube. The flasks were washed 
with an additional 3 ml of growth medium and the wash fluid 
was added to the harvested cells. The tubes were centrifuged 
in a Beckman TJ-6 tabletop centrifuge for 10 min at 2000 rpm 
at room temperature. All but 0.5 ml of fluid was removed and 
the tube was vortexed to resuspend the cells. The cells were 
then transferred to microcentrifuge tubes. One milliliter of 
phosphate buffered saline (PBS) was added to the tubes. The 
tubes were centrifuged at 12,000 x g for 5 min at 4°C. The 
fluid was removed and the cells were washed twice with 1 ml 
of PBS in a similar manner. PBS was added to the tubes to a 
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final volume of 200 µl. The tubes were then vortexed to 
resuspend the cells. Sixty-five microliters of 2.0 M 
perchloric acid was added to each tube. The tubes were 
vortexed and centrifuged for 30 min. The supernatant 
containing the cell extracts was transferred to a new 
microcentrifuge tube and placed on ice prior to HPLC analysis 
or stored at -70°C. 
Phosphorylated products of GCV metabolism were.separated 
by HPLC using the method of Lurain (76). The mobile phase was 
o. 02 M KH2P04 pH 3. 65 run at a flow rate of o. 3 ml/min. 
Briefly, 10 µl of GCV standard { 100 µM GCV, 100 µM GCV-
monophosphate) was injected and run through a Partisil 10 OD3 
250 x 4.6 mm reverse phase HPLC column {Phenomenex, Rancho 
Palos Verdes, CA). One hundred microliters of the perchloric 
acid extracts of infected cells was injected and fractions 
were collected in scintillation vials at 0.3 min intervals for 
15 min. Seven milliliters of scintillation fluid {Ultima 
Gold, Packard Instrument Company, Meriden, CT) was added to 
each vial and the radioactivity of each vial was measured for 
2 min using an LKB 1214 Rackbeta liquid scintillation counter. 
Bacterial plasmid DNA Isolation. Miniprep plasmid DNA 
isolation was performed using a modified alkaline lysis 
protoco 1 (7 8) . Two ml of Luria Broth {Gibco BRL, Grand 
Island, NY) containing the appropriate selective antibiotic 
was inoculated with a single bacterial colony and incubated 
overnight at 37°C with shaking. The culture was transferred 
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to a 2 ml microcentrifuge tube and the cells were pelleted by 
centrifugation at 12, ooo x g for 1 min. The medium was 
removed and cells were resuspended in 0.1 ml ice-cold lysis 
solution containing 50 mM glucose, 10 mM EDTA, and 25 mM Tris-
HCl pH 8. O. The tube was incubated for 5 min at room 
temperature. Two hundred microliters of a freshly prepared 
solution of 0.2 N NaOH, 1% sos was added and the contents were 
mixed by gentle inversion. Following incubation for 5 min at 
room temperature, 0.15 ml of ice-cold 5 M potassium acetate 
solution pH 4.8 was added followed by incubation on ice for 
10 min. The tube was centrifuged for 5 min at 12,000 x g and 
the supernatant was transferred to a fresh tube. An equal 
volume of ·phenol saturated with 50 mM Tris pH 8.0:chloroform: 
isoamyl alcohol (50:48:2) was added and tubes were centrifuged 
at 12, 000 x g for 5 min. The upper aqueous layer was 
transferred to a fresh tube. Plasmid DNA was precipitated by 
the addition of 2 volumes of ice-cold 95% EtOH. DNA was 
pelleted by centrifugation at 12, ooo x g for 10 min. The 
supernatant was decanted and the pellet was washed with 1 ml 
of 70% EtOH. The DNA pellet was dried and resuspended in 30 
µl of TE containing RNase (20 µg/ml). DNA concentration was 
estimated using agarose gel electrophoresis with known DNA 
standards. 
For large-scale isolation of plasmid DNA, 200 ml of 
CircleGrow medium (BiolOl, LaJolla, CA) containing the 
appropriate selective antibiotic was inoculated · with an 
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isolated colony of ~- coli and incubated at 37°C with shaking 
overnight. The bacteria were pelleted by centrifugation at 
5, ooo x g for 10 min in the Sorvall GSA rotor. The pellet was 
resuspended in 5 ml of a solution containing 50 mM glucose, 
25 mM Tris-HCl pH 8. o, and 10 mM EDTA. The fluid was 
transferred to 40 ml Oak Ridge tubes and an additional 5 ml 
of the same solution containing 10 mg/ml of lysozyme was 
added. After incubation for 5 min at room temperature, 20 ml 
of 0.2 N NaOH/1% SOS was added followed by incubation for 5 
min at room temperature. Fifteen milliliters of ice-cold 5 
M potassium acetate solution (pH 4.8) were added, the contents 
were mixed by vigorous shaking and incubated on ice for 10 
min. The tube was centrifuged in the Sorvall SS34 rotor for 
30 min at 25,000 x g. The supernatant was transferred to two 
30 ml Corex tubes (18 ml/tube), 12 ml of isopropanol was 
added, and the tubes were incubated at room temperature for 
20 min. The tubes were centrifuged in the SS 34 rotor at 
8,000 x g for 30 min at room temperature. The pellets were 
resuspended in 3 ml of TE and pooled. The volume was adjusted 
to 6. 6 ml with TE. Cesium chloride (7. 245 g) was added 
followed by 0.54 ml of 10 mg/ml ethidium bromide. The DNA 
solution was divided between three 3. 5 ml Quik-Seal tubes 
which were then centrifuged in the Sorvall TLl00.3 rotor at 
300,000 x g for 5 h. Plasmid bands were harvested from the 
tubes by side puncture. The ethidium bromide was extracted 
with isopropanol saturated with lOX SSC (3 M NaCl, O. 3 M 
sodium citrate, pH 7. O). 
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The DNA was precipitated by the 
addition of an equal volume of TE and then 2 volumes of 95% 
EtOH followed by incubation at -20°c for 1 h. DNA was 
pelleted in microcentrifuge tubes by centrifugation at 12,000 
x g for 10 min. The DNA pellets were resuspended in 0.2 ml 
of TE. DNA concentration was determined 
spectrophotometrically (78). 
Agarose gel electrophoresis. Viral and . bacterial 
plasmid DNA samples were analyzed on horizontal 0.7% agarose 
gels containing 0.12 µg/ml ethidium bromide in buffer 
containing 89 mM Tris base, 89 mM boric acid, and 2 mM 
disodium EDTA (final pH 8.0). 
Cloning of· restriction fragments. 
linearized with EcoRI and treated 
pUC18 vector DNA was 
with calf alkaline 
phosphatase (CIP) (Boehringer Mannheim, Indianapolis IN) . 
HCMV genomic DNA was digested with · EcoRI, ethanol 
precipitated, and redissolved in distilled water and stored 
at -20°c. HSV genomic DNA was digested with EcoRI 
fragments were separated by agarose gel electrophoresis. 
and 
The 
band of interest was excised and the DNA was electroeluted and 
purified by ethanol precipitation. Ligation of 0.5 µg vector 
and 0.5 µg insert DNA was carried out in 60 mM Tris-HCl pH 
8.0, 33 mM NaCl, 10 mM MgC12 , 1 mM ATP, and 1 unit of T4 ligase 
(Stratagene, LaJolla, CA) in a total volume of 50 µl for 2 h 
at room temperature. Control ligations contained only CIP-
treated or CIP-untreated vector DNA. 
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competent cells were prepared as follows. A 1 ml Luria 
broth preculture was inoculated with a single colony of E. 
coli DH5a and incubated overnight at 37°C with shaking. Two ------
hundred microliters of the overnight culture was added to 19.8 
ml of Luria broth and the culture was incubated for 2-3 h at 
37°c with shaking. The bacteria were pelleted by 
centrifugation in a Sorvall SS34 rotor at 3,000 x g for 5 min 
at 4°C. Pelleted cells were resuspended in 5 ml ice-cold 50 
mM CaC12 and held on ice for 20 min. The bacteria were 
pelleted as before, gently resuspended in 1 ml ice-cold 50 mM 
cacl2 , and placed on ice until use. 
Ligation products were transformed into competent E· coli 
DH5a cells. The ligation mixes were added to 100 µl competent 
cells in prechilled 17 x 100 mm tubes. The suspensions were 
held on ice for 1 h followed by 42°C incubation for 2 min. 
One ml of Luria broth prewarmed at 37°C was added to the tube. 
Cultures were incubated for 1 h at 37°C with shaking. Four 
aliquots (0.25 ml) were plated on Luria agar plates containing 
100 µg/ml ampicillin. Plasmid DNA from resultant colonies was 
isolated, digested with various restriction endonucleases, and 
analyzed by agarose gel electrophoresis. 
Preparation of labelled probes. Plasmid DNA was labelled 
with 32P by random priming (Multiprime Labelling Kit; Amersham, 
Arlington Heights, IL) according to the manufacturer's 
instructions. Unincorporated nucleotides were separated from 
the .labelled probes using spin columns (5 '-->3', Inc., West 
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chester, PA}. 
southern hybridizations. Agarose gels were depurinated 
in o.4 M HCl for 10 min at room temperature, denatured in 0.5 
M NaOH/1.0 M NaCl for 30 min, and neutralized in 0.5 M Tris-
HCl/1.5 M NaCl (final pH 7.4) for 30 min. All incubations 
were performed at room temperature. The gels were then 
blotted overnight onto Nytran {Scheicher and Schuell, Keene, 
NH} with lOX SSPE {lX SSPE is 0.18 M NaCl, 10 mM NaH2P04 , 1 mM 
EDTA). After briefly rinsing the membranes in 2X SSPE, the 
DNA was UV crosslinked to the membrane using the UV 
stratalinker (Stratagene, La Jolla, CA} set on auto crosslink. 
The membranes were prehybridized in 1% sos, 6X SSPE, lOX 
Denhardt's solution, and 50 µg/ml denatured salmon sperm DNA 
for 1-2 h at 42°C. The prehybridization fluid was replaced 
with solution containing 50% formamide, 1% sos, 6X SSPE, 50 
µg/ml of denatured salmon sperm DNA, and 10 ng denatured probe 
DNA. 
The membranes were washed twice with 2X SSPE for 15 min 
at room temperature, twice with 2X SSPE/0.1% sos for 15 min 
at 65°C ' and twice with 
0.1% SSPE at room temperature. 
Membranes were placed on Whatman 3M paper, covered with 
plastic wrap and placed in X-ray cassettes with Crones 
Lightning Plus intensifying screens (DuPont, Wilmington, DL} 
and Kodak X-OMAT AR film. Cassettes with held at -70°C 
overnight. 
DNA sequence analysis. DNA sequence analysis performed 
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using the Sanger dideoxy termination method ( 103) . DNA 
sequencing reactions were performed using the T7 DNA 
sequencing kit (Pharmacia LKB Biotechnology Inc., Piscataway, 
NJ) or the TaqTrack sequencing system (Promega Corporation, 
Madison, WI) according to the manufacturer's instructions. 
Reaction products were electrophoresed through a 0.4 mm 6% 
polyacrylamide/7.56 M urea gel at 60 watts. 
Site-directed in vitro mutaqenesis. In vitro mutagenesis 
was performed using the Altered Sites Mutagenesis System 
(Promega Corporation, Madison, WI) according to the 
manufacturer's instructions. For the mutagenesis reaction, 
a synthetic oligonucleotide complementary to a region of the 
HCMV DNA polymerase was synthesized at the LUMC Macromolecular 
Facility. The sequence of the 16-mer is as follows: 5' 
GTTCTGTGACAGCGG. The underlined base corresponds to the 
mismatch of adenosine in the complementary strand at 
nucleotide position 3048 in the HCMV AD169 sequence (71). 
Incorporation of the mismatched base was confirmed by DNA 
sequence analysis. 
Transfection of mammalian cells. The procedure of Cai 
et al. (11) was followed for transfection of HFF and Vero 
cells. DNA for transfection was precipitated by addition of 
the following components in the following order: sterile 
distilled water to final volume, salmon sperm DNA (40 µg/ml), 
plasmid DNA (6.6 µg/ml), HSV-1 KOS or HCMV AD169 DNA (0.2 
µg/ml), calcium chloride (final concentration= 0.25 M), and 
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one-tenth volume of 2X Hepes buffered saline pH 7.04 {HBS). 
The mixture was allowed to sit at room temperature for 30 min. 
During this time, a slightly cloudy precipitate formed. The 
medium was removed from HFF or Vero cell monolayers in 100 mm 
dishes and replaced with 3 ml/plate of the cacl-DNA 
precipitate. After 30 min incubation at 37°C in 5% co2 , 7 ml 
of growth medium was added to the monolayers. 
After 4 h incubation at 37°C in 5% co2 , the cells were 
shocked with glycerol as follows. The medium was replaced 
with 3 ml of maintenance medium containing 15% glycerol and 
monolayers were incubated at room temperature for 1 min. The 
shock medium was removed and the cells were washed twice with 
maintenance medium. The monolayers were then overlaid with 
10 ml of growth medium with or without antiviral drug and 
incubated at 37°C in 5% co2 until confluent. The medium was 
replaced weekly with maintenance medium until substantial 
plaque formation was observed. 
RESULTS 
Development of an in situ ELISA for a late HCMV antigen. 
Recent studies have described the development of in situ ELISA 
assays for the quantitation of HSV (2,97) and VZV (5) antigens 
in infected monolayers. We have adapted these protocols for 
the quantitation of an HCMV late nuclear antigen. 
The VZV protocol described by Berkowitz and .Levin (5) 
was used with following modifications. First, a primary 
monoclonal antibody against a HCMV late nuclear antigen was 
chosen rather than an early antigen since synthesis of a late 
antigen was strictly dependent on viral DNA synthesis and 
therefore was directly related to virus reproduction. Second, 
preliminary experiments showed that fixation of cell 
monolayers with ethanol:acetone (95:5) was far superior to 
fixation with glutaraldehyde. 
Initial experiments were performed to determine the 
optimum virus inoculum concentration. Monolayers of HFF in 
96-well microtiter plates were inoculated with increasing 2-
fold concentrations of HCMV strain AD169. The ELISA was 
performed when the CPE in the wells containing the highest 
concentration of virus (MOI = o. 1) reached 100% ( 4+) . At that 
time, 25% CPE was observed in the monolayers inoculated with 
the lowest concentration of virus (MOI = 3. 9 x 10-4 ) • The 
relationship between MOI and OD450 is shown in Figure 4. A low 
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Figure 4. 
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Relationship between MOI and OD450 for detection 
of a late HCMV antigen in the ELISA assay. 
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level of viral antigen was detected in monolayers infected 
with the lowest concentration of virus and with the least CPE. 
A linear relationship between MOI and 00450 existed between an 
MOI of 3 .1 x 10-3 and 2. 5 x 10-2 • These inoculum 
concentrations resulted in 25 to 50% CPE (2-3+). At the 
higher MO! (~0.05) and therefore the higher CPE, the 
monolayers began to disintegrate resulting in a loss of viral 
antigen. This was reflected in a plateau in. the 00450 
readings. These results indicated that optimum results were 
obtained when the CPE involved 25-50% of the infected 
monolayer (2-3+ CPE). 
Adaptation of the ELISA for HCMV susceptibility testing. 
Experiments were performed to determine the effect of MO! on 
susceptibility testing of HCMV A0169 using the ELISA assay. 
Four 96-well plates seeded with HFF were inoculated with HCMV 
A0169 at four different MOI. The monolayers in each plate 
were then incubated in the presence or absence of various 
concentrations of GCV, ACV, PAA, or PFA. The ELI SA was 
performed when the CPE in the virus control wells (medium 
without drug) reached 2 to 3+ (4 to 7 days post-infection). 
The relationship between the IC50 and MOI for GCV 
susceptibility is shown in Figure 5. At the lowest MO! tested 
(0.005), the IC50 for GCV was 1.6 µM. Increasing the MO! ten-
fold to O. 05 increased the IC50 to 25 µM. Therefore, the IC50 
value of GCV was MOI dependent. Similar results were obtained 
for PFA, PAA, and ACV (Table 1). Therefore, in order to 
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Relationship between MOI and the IC50 for GCV 
using the ELISA assay. MOI = o. 005 {open 
triangle), MOI = 0.01 {open diamond), MOI = 
0.025 {X), MOI =· 0.05 {closed squares). 
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Table 1. Effect of MOI on IC50 values 
AD169 using the ELISA. 
for HCMV strain 
ICso (µM) 
MOI GCV ACV PFA PAA 
0.005 1. 6 50 62.5 18 
0.012 3.1 50 62.5 18 
0.025 25 >100 250 45 
0.05 25 >100 250 45 
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standardize the assay, an MOI of 0.012 was chosen for use in 
further studies. At this MOI, the IC50 value of HCMV strain 
AD169 as determined by the ELISA approximated the IC50 value 
for GCV using the plaque reduction assay {20,43,123, Tables 
2 and 4). 
To further test the accuracy of the ELISA for 
susceptibility testing, susceptibility profiles of two GCV-
resistant laboratory-derived mutants of HCMV strain AD169 were 
determined using the ELISA and the PRA. These results are 
summarized in Table 2. Both mutants were previously shown to 
be deficient in GCV-kinase activity and therefore remained 
susceptible to DNA polymerase inhibitors {76). The ELISA 
clearly demonstrated that the mutants were susceptible to PAA, 
PFA, and aphidicolin and hypersensitive to AraA and AraT. The 
data show that though the numerical values of the IC50 may 
differ between the two assays, resistance can be determined 
using either assay. 
Also, an additional experiment revealed that regardless 
of the inoculum size used, resistance can be detected using 
the ELISA. At an MOI of 0.015, the IC50 values for AD169 and 
06/3/1 were 3.1 µMand 100 µM, respectively. When the MOI was 
increased to o. 06, the IC50 values for AD169 and 06/3/1 
increased to 50 µM and 200 µM, respectively. Therefore, the 
inoculum size does not affect the relative IC50 results when 
the test virus and control virus AD169 are used at the same 
MOI. 
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Table 2. HCMV susceptibility testing using the ELISA 
and PRA. 
ICso (µM) 
Assay and 
virus tested8 GCV ACV PAA PFA AraA AraT Aph 
ELISA 
A0169 6.2 200 45 150 100 1000 3.8 
06/3/lb 200 150 90 150 25 150 3.8 
01/3/4b 200 250 90 200 25 150 3.8 
PRA 
A0169 6.2 150 180 300 125 >1000 5 
06/3/1 200 150 180 300 50 300 5 
01/3/4 200 150 180 300 50 100 5 
8MOI = O. 012 
bLaboratory derived GCV-resistant mutants of HCMV strain 
A0169 (76) • 
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Collection and growth of HCMV clinical isolates from 
LUMC. Clinical isolates of HCMV from transplant patients at 
LUMC were collected from the clinical microbiology laboratory 
over a 27 month period. During that time, GCV therapy for 
HCMV disease was available for these patients. We hoped to 
collect pre-treatment, during-treatment, and post-treatment 
isolates. Any virus isolated during- or post-treatment would 
theoretically be GCV-resistant. 
Most isolates from the clinical microbiology laboratory 
displayed very little CPE in the initial isolation tubes. 
Cells from these tubes were harvested by scraping and used to 
inoculate fresh HFF tubes. Cultures were incubated for 5 
weeks. This process was repeated until the virus became 
extracellular (100% CPE) and aliquots of the culture fluid 
were stored at -70°C. Virus from the clinical isolates became 
extracellular between pass 3 and pass 11, with an average of 
approximately 6-8 passes. Eighty-three clinical isolates were 
collected in this manner. All virus strains were isolated 
from patients prior to any GCV therapy. All patients remained 
virus-free during therapy and post-treatment or expired during 
treatment. 
Initial screening of GCV-susceptibility of clinical HCMV 
isolates. In order to perform GCV susceptibility testing of 
these isolates, the titer of each virus stock was determined. 
Plaque dilution assays were performed on all frozen stocks. 
Of the 83 isolates screened, 9 isolates grew to high enough 
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titer (~103 pfu/ml) to be screened for GCV susceptibility 
using the ELISA assay. 
The nine isolates were tested for susceptibility to GCV 
using the ELISA assay. Eight of the isolates appeared to be 
GCV-sensitive as compared to the AD169 control (Table 3) while 
the ninth, H51856, appeared to be resistant (IC50 = 50 µM). 
Multiple testing of isolate H51856 yielded similar results. 
GCV-resistant strain H51856, cultured from a bronchial wash 
specimen, and GCV-sensitive strain H51853, cultured from a 
blood specimen, were collected from the same patient on the 
same day. Both specimens were obtained prior to GCV treatment 
for HCMV disease. No virus was isolated from the patient 
during or post-treatment. These two isolates were chosen for 
further investigation for two reasons. First, isolate H51856 
was a source of GCV-resistant HCMV. Second, because isolates 
H51856 and H51853 were isolated from the same patient on the 
same day, comparisons could be made between the two strains. 
Several studies have shown that clinical isolates of HSV 
were actually mixtures of both drug-resistant and drug-
sensi ti ve strains (18,37,81,94). Therefore, to determine the 
percentage of GCV-resistant virus in strain H51856, a percent 
survival assay was performed. Monolayers of HFF were 
inoculated with ten-fold dilutions of H51856 and incubated in 
the presence and absence of 12.5 µM GCV. Comparison of titers 
in the absence of GCV (6 x 104 pfu/ml) and in the presence of 
GCV (< 1 x 102 pfu/ml) revealed that less than 1% of the 
Table 3. GCV susceptibility testing of HCMV clinical 
isolates using the ELISA. 
ICso (µM) 
Clinical isolate Test AD169, control 
543096 6.2 6.2 
H46893 1.6 3.1 
542651 1. 6 6.2 
T1840 12.5 6.2 
W66730 1. 6 3.1 
515165 <0.8 3.1 
M25527 3.1 3.1 
H51853 3.1 6.2 
H51856 50 6.2 
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population was GCV-resistant. In order to purify the GCV-
resistant subpopulation of H51856, two rounds of plaque 
purification were performed in the presence of 12.5 µM GCV. 
Two clones, D13 and D16, were chosen for further study. Both 
clones exhibited growth characteristics (e.g. growth rate, 
titer) similar to wild-type HCMV strain AD169 (data not 
shown). 
Antiviral susceptibility profiles of GCV-resistant H51856 
clones D13 and D16. The plaque reduction assay (PRA) and the 
ELISA assay were performed to determine the antiviral 
susceptibility profiles of H51856 clones Dl3 and Dl6. Both 
the PRA and the ELISA confirmed that the two clones were GCV-
resistant (Table 4). Using the PRA, both clones showed only 
a two-fold increase in resistance to the DNA polymerase 
inhibitor phosphonoformic acid (PFA). However, susceptibility 
testing using the ELISA revealed that D13 and D16 were indeed 
PFA-resistant (IC50 = 625 µMand 1250 µM, respectively). The 
ELISA IC50 values for PFA were at least 4-fold higher for the 
GCV-resistant clones as compared to wild-type HCMV strain 
AD169. Similar results were obtained with another DNA 
polymerase inhibitor, phosphonoacetic acid (PAA). These 
results indicate that GCV-resistance was due to either a 
mutation in the viral DNA polymerase gene alone or in 
conjunction with a mutation in the ability of the virus to 
monophosphorylate the nucleoside analog GCV. Further testing 
was performed using the nucleoside analogs HPMPA and HPMPC. 
60 
Table 4. Antiviral susceptibility profile of H51856 
clones. 
ICso (µM) 
Assay and 
virus tested GCV PFA PAA HPMPA HPMPC 
ELISA 
A0169 6.2 156 45 <0.06 <0.06 
013 >200 625 360 N. 0. a N.O. 
016 >200 1250 360 8 0.5 
PRA 
A0169 6.2 200 125 0.25 0.12 
013 50 400 N.O. 2 4 
016 50 800 250 4 1 
8N .O. = not done 
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since these two compounds are monophosphate nucleoside 
derivatives, viral-induced kinase activity is not necessary 
for activation of the drugs (90) . The drugs are 
phosphorylated to the active triphosphate form by cellular 
kinases. Clones D13 and D16 were resistant to HPMPA and HPMPC 
in both the PRA and ELISA assays (Table 4) suggesting that the 
mutation conferring GCV-resistance is probably at the level 
of the viral DNA polymerase gene. 
GCV anabolism in HCMV-infected HFF. Two GCV-resistant 
laboratory mutants of strain AD169, BW B759rD100 and D6/3/1, 
have been reported (7, 76). Analysis of infected cell extracts 
showed that both were unable to phosphorylate GCV at levels 
comparable to wild-type HCMV strain AD169. However, both 
remained sensitive to the viral DNA polymerase inhibitors PFA 
and PAA. These observations suggested that a mutation in the 
gene involved in monophosphorylation of GCV was responsible 
for drug resistance. Therefore, similar GCV anabolism studies 
were performed using HCMV strain AD169-, Dl3-, Dl6-, or 
D6/3/1-infected HFF. Two days post-infection, the cultures 
were incubated for an additional 24 h in the presence of 3H-
GCV. Infected cell extracts were analyzed for GCV anabolism 
products using HPLC. 
Previous analysis of HPLC fractions of infected cell 
extracts showed that phosphorylated derivatives of 3H-GCV 
eluted between fractions 5 and 15 while unphosphorylated 3H-
GCV eluted between fractions 30 and 40 (76). However, this 
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assay cannot resolve the individual phosphorylation products 
of GCV. Experiments here confirmed that little, if any, GCV 
phosphorylation occurred in mock infected cells (Figure 6). 
The peak height of phosphorylated GCV derivatives is half that 
of non-phosphorylated GCV. However, significant GCV 
phosphorylation was induced in wild-type AD169 infected HFF 
(Figure 6}. The peak height of phosphorylated GCV derivatives 
is comparable, if not higher, than non-phosphorylated GCV. 
GCV anabolism profiles of clones D13 and Dl6 were nearly 
identical to the wild-type HCMV strain AD169 profile (Figure 
6} suggesting that GCV-resistant clones induced wild-type 
levels of GCV phosphorylation. 
In a second similar experiment, the induction of GCV 
phosphorylation by D13 and the GCV-kinase mutant D6/3/1 was 
compared (Figure 7). strain D13 induced GCV phosphorylation 
at levels comparable to wild-type HCMV strain AD169. In 
contrast, strain D6/3/1 showed a decreased level of induction 
of GCV phosphorylation as compared to strain AD169 and strain 
D13. These data, taken in conjunction with the antiviral 
susceptibility profiles of Dl3 and D16, suggest that the 
virus-induced GCV-kinase activity is intact and that a 
mutation in the viral DNA polymerase gene is responsible for 
GCV-resistance. 
Genomic location of the H51856 Dl3 and H51853 DNA 
polymerase genes. The HCMV DNA polymerase gene of HCMV strain 
AD169 is located on a 7.1 kb EcoRI M fragment (Figure 8}. In 
Figure 6. 
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GCV phosphorylation products in mock-, A0169-
, 013-, and 016-infected HFF. Phosphorylated 
derivatives of 3H-GCV elute between fractions 
5 and 15. Unphosphorylated 3H-GCV elutes 
between fractions 30 and 40. The mobile phase 
was 0.02 M KH2P04 pH 3.65 run at a flow rate of 
0.3 ml/min through a Partisil 10 003 column. 
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GCV phosphorylation products in AD169-, 013-, 
and 06/3/1-infected HFF. Phosphorylated 
derivatives of 3H-GCV elute between fractions 
5 and 15. Unphosphorylated 3H-GCV elutes 
between fractions 30 and 40. HPLC conditions 
are described in Figure 6. 
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Restriction endonuclease map of HCMV strain 
AD169 (reproduced with permission from 
reference 76). 
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order to locate the HCMV DNA polymerase genes from the GCV-
resistant clone D13 and its corresponding GCV-sensi ti ve strain 
H51853, EcoRI digests of extracellular viral DNA were 
analyzed by agarose gel electrophoresis (Figure 9A). 
comparison of EcoRI restriction digest profiles between D13 
and H51853 showed very few differences (lanes 4 and 5). 
However, several differences were noted between the clinical 
isolates and wild-type strain AD169 (lane 3) . Similar results 
were seen with BamHI digests (lanes 6 - 8) . The BglII 
restriction digests of Dl3 and H51853 appeared identical 
(lanes 10 - 11) but slightly different than AD169 BglII 
digests (lane 9). The digested DNA was then transferred by 
Southern blotting and probed with pEcoM, a pUC18-derived 
plasmid construct containing the AD169 EcoRI M fragment. The 
probe hybridized to the 2.6 kb vector DNA band and to the EcoM 
fragment of pEcoM (Figure 9B, lane 2). The probe hybridized 
to one EcoRI viral fragment each in the pEcoM, AD169, D13, and 
H51853 digests (Figure 9B, lanes 3 - 5). The size of the Dl3 
and H51853 hybridizing fragments were approximately 1 kb 
larger than the AD169 EcoRI M fragment. Since the probe 
hybridized to only one fragment in the D13 and H51853 digests, 
the viral DNA polymerase gene must lie within this fragment. 
Cloning of the D13 and H51853 DNA polymerase genes. 
Genomic DNA from strains Dl3 and H51853 was digested with 
EcoRI, ligated with EcoRI-digested pUC18 vector plasmid DNA, 
and transformed into ~- coli DH5a. Transformant plasmid DNA 
Figure 9. 
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Agarose gel (A) with corresponding Southern 
blot (B) of restriction endonuclease digested 
AD169, GCV-resistant D13, and GCV-sensi ti ve 
H51853 viral DNA. Probe was pEcoM and lambda 
DNA. Sizes of the fragments in lanes 1 and 13 
are 23.1, 9.4, 6.6, 4.4, 2.3, 2.0, and 0.6 kb. 
DNA: Lambda 
pEcoM 
AD169 
013 
H51853 
Enzymes: HindIII 
Eco RI 
BamHI 
BglII 
Lanes 1 and 13 
Lanes 2 and 12 
Lanes 3, 6, and 9 
Lanes 4, 7, and 10 
Lanes 5, a, and 11 
Lanes 1 and 13 
Lanes 2 - 5, 12 
Lanes 6 - 8 
Lanes 9 - 11 
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was isolated and digested with EcoRI and analyzed by agarose 
gel electrophoresis. Those clones with inserts approximately 
a kb in size were selected and further analyzed. 
Recombinant plasmid DNA and pEcoM plasmid DNA were 
digested with EcoRI, EcoRI and BamHI, or EcoRI and BglII and 
separated by agarose gel electrophoresis (Figure lOA). 
Digestion with EcoRI alone should yield a 2.7 kb linear vector 
fragment and insert viral DNA. Viral inserts . from two 
plasmids, pD13M (lane 3) and p53POL (lane 4), comigrated at 
approximately 8 kb, slower than the 7.1 kb HCMV strain AD169 
EcoRI M fragment in pEcoM (lane 2). A third plasmid, pl70, 
harbored a D13 EcoRI insert larger than pD13M and p53POL (lane 
5). Double restriction digests with EcoRI and BamHI (lanes 
6-9) and EcoRI and BglII (lanes 10-13) revealed that pD13M and 
p53POL shared several common fragments with pEcoM while p107 
showed very little similarity with pD13M, p53POL and pEcoM. 
The digested DNA was then transferred by Southern 
blotting and probed with pEcoM (Figure lOB). The probe 
hybridized to the 2.7 kb vector DNA and to the AD169 EcoRI M 
insert in pEcoM (lane 2). The probe also hybridized to the 
vector DNA and to the two larger inserts in pD13M and p53POL 
(lanes 3 and 4). However, the probe hybridized only to the 
vector DNA in pl07 (lane 5). Analysis of hybridization 
patterns of double restriction digests (lanes 6-13) using 
restriction maps of HCMV strain AD169 (Figure 8) confirmed 
that pD13M and p53POL harbored an EcoRI insert which encoded 
Figure 10. 
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Agarose gel (A) with corresponding 
Southern blot (B) of restriction 
endonuclease digested pEcoM and plasmid 
clones containing 013 EcoRI inserts. 
Probe was pEcoM and lambda DNA. Sizes of 
the fragments in lanes 1 and 14.are 23.1, 
9.4, 6.6, 4.4, 2.3, 2.0, and 0.6 kb. 
Lambda 
pEcoM 
p013M 
p53POL 
pl07 
Lanes 1 and 14 
Lanes 2, 6, and 10 
Lanes 3 , 7 , and 11 
Lanes 4, 8, and 12 
Lanes 5, 9, and 13 
Enzymes: HindIII 
EcoRI 
EcoRI/BamHI 
EcoRI/BglII 
Lanes 1 and 14 
Lanes 2 - 5 
Lanes 6 - 9 
Lanes 10 - 13 
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the viral DNA polymerase gene. The slight differences in 
restriction and hybridization patterns between the 
recombinants pD13M and p53POL and the wild-type pEcoM in the 
double digests were probably due to the additional 1 kb of 
viral DNA in the pD13M and p53POL viral EcoRI inserts. Since 
the pEcoM probe hybridized to only one insert band in EcoRI 
digests of genomic D13 and H51853 DNA, this suggested that 
pD13M and p53POL EcoRI inserts encoded the entire.viral DNA 
polymerase gene. Therefore, pD13M and p53POL were chosen for 
further study. 
Sequence analysis of the D13 and H51853 DNA polymerase 
genes. Previous studies have demonstrated that DNA polymerase 
drug-resistant mutants of HSV and vaccinia virus contain 
nucleotide base substitutions in specific conserved areas of 
the viral DNA polymerase gene (49,118). All HSV mutations 
were mapped to one region, the proposed deoxynucleotide 
triphosphate (dNTP} and pyrophosphate (PPi} binding sites 
(50}. Significant homology exists between the HSV, EBV, and 
HCMV DNA polymerase proteins at these two sites (71}. 
Therefore, sequence analysis was performed on these homologous 
areas of the DNA polymerase genes of GCV-resistant clone D13 
and the GCV-sensitive strain H51853. Based on the published 
sequence of the AD169 DNA polymerase gene (71}, the homology 
to the HSV dNTP and PPi binding sites occurs between bases 
2145 and 3503. The published sequence of HCMV AD169 and the 
sequence data for HCMV GCV-resistant clone D13 and GCV-
76 
sensitive clone H51853 are shown in Figure 11. Out of 1358 
bases, only 21 changes were observed in D13 and 21 in H51853. 
seventeen of the 21 changes were shared in both strains. 
Analysis of the amino acid sequence generated by these 
nucleotide sequences is shown in Figure 12. In HSV-1, the 
proposed dNTP and PPi binding sites lie on a continuous 
stretch of the DNA polymerase protein. However, the HCMV DNA 
polymerase protein contains several additional stretches of 
amino acids which separate the homology to the HSV dNTP and 
PPi binding sites. Of the shared nucleotide changes, only two 
changes would result in altered amino acids when compared to 
GCV-sensitive wild-type HCMV strain AD169. At amino acid 
number 685, there is a conservative asparagine (N) to serine 
(S) change and at position number 691, there is a conservative 
threonine (T) to serine (S) substitution. Of the non-shared 
nucleotide changes, two substitutions in the GCV-sensitive 
strain H51353 polymerase gene would result in adjacent non-
conservative amino acid changes. Glutamine (Q) (position 651) 
and aspartic acid (D) (position 652) would be replaced with 
histidines (H). The wild-type glutamine and aspartic acid at 
positions 651 and 652 are not conserved in the HSV or EBV 
polymerase proteins (71). Most strikingly, only one non-
shared amino acid substitution was observed in the GCV-
resistant clone D13, a relatively non-conservative alanine 
(A} to threonine (T) substitution at amino acid position 885. 
This mutation is located between two areas of homology with 
Figure 11. 
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Nucleotide sequence of the proposed dNTP and 
PPi binding sites of the HCMV AD169, 013 and 
H51853 DNA polymerase genes. The right most 
number of the nucleotide position is positioned 
above the corresponding base. Base 
substitutions in the 013 and H51853 genes are 
shown below the AD169 sequence. 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
AD169 
Dl3M 
53POL 
2148 2239 
TCGCCCAACTATAAGCTCAACACTATGGCCGAGCTTTACCTGCGGCAACGCAAGGATGACCTGTCTTACAAGGACATCCCGCGTTGTTTCGTGGC 
c 
c 
2243 2334 
TAATGCCGAGGGCCGCGCCCAGGTAGGCCGTTACTGTCTGCAGGACGCCGTATTGGTGCGCGATCTGTTCAACACCATTAATTTTCACTACGAGG 
2338 2429 
CCGGGGCCATCGCGCGGCTGGCTAAAATTCCGTTGCGGCGTGTCATCTTTGACGGACAGCAGATCCGTATCTACACCTCGCTGCTGGACGAGTGC 
G T 
G T 
2433 2524 
GCCTGCCGCGATTTTATCCTGCCCAACCACTACAGCAAAGGTACGACGGTGCCCGAAACGAATAGCGTTGCTGTGTCACCTAACGCTGCTATCAT 
c c 
c 
2528 2619 
CTCTACCGCCGCTGTGCCCGGCGACGCGGGTTCTGTGGCGGCTATGTTTCAGATGTCGCCGCCCTTGCAATCTGCGCCGTCCAGTCAGGACGGCG 
G 
G TC 
2623 2714 
TTTCACCCGGCTCCGGCAGTAACAGTAGTAGCAGCGTCGGCGTTTTCAGCGTCGGCTCCGGCAGTAGTGGCGGCGTCGGCGTTTCCAACGACAAT 
G 
G 
2718 2809 
CACGGCGCCGGCGGTACTGCGGCGGTTTCGTACCAGGGCGCCACGGTGTTTGAGCCCGAGGTGGGTTACTACAACGACCCCGTGGCCGTGTTCGA 
T GC A 
T GC A 
2813 2904 
AD169 CTTTGCCAGCCTCTACCCTTCCATCATCATGGCCCACAACCTCTGCTACTCCACCCTGCTGGTGCCGGGTGGCGAGTACCCTGTGGACCCCGCCG 
Dl3M T C T 
53POL T C T 
2908 2999 
AD169 ACGTATACAGCGTCACGCTAGAGAACGGCGTGACCCACCGCTTTGTGCGTGCTTCGGTGCGCGTCTCGGTGCTCTCGGACCTGCTCAACAAGTGG 
Dl3M T 
53POL T 
3003 3094 
AD169 GTTTCGCAGCGGCGTGCCGTGCGCGAATGCATGCGCGAGTGTCAAGACCCTGTGCGCCGTATGCTGCTCGACAAGGAACAGATGGCGCTCAAAGT 
Dl3M 
53POL 
3098 3189 
AD169 AACGTGCAACGCTTTCTACGGTTTTACCGGCGTGGTCAACGGTATGATGCCGTGTCTGCCCATCGCCGCCAGCATCACGCGCATCGGTCGCGACA 
Dl3M T 
53POL T C 
3193 3284 
AD169 TGCTAGAGCGCACGGCGCGGTTCATCAAAGACAACTTTTCAGAGCCGTGTTTTTTGCACAATTTTTTTAATCAGGAAGACTATGTAGTGGGAACG 
Dl3M A C 
53POL 
3288 3379 
AD169 CGGGAGGGGGATTCGGAGGAGAGCAGCGCGTTACCGGAGGGGCTCGAAACATCGTCAGGGGGCTCGAACGAACGGCGGGTGGAGGCGCGGGTCAT 
Dl3M A G A 
53POL G A 
3373 3474 
AD169 CTACGGGGACACGGACAGCGTGTTTGTCCGCTTTCGTGGCCTGACGCCGCAGGCTCTGGTGGCGCGTGGGCCCAGCCTGGCGCACTACGTGACGG 
Dl3M 
53POL T 
3478 3503 
AD169 CCTGTCTTTTTGTGGAGCCCGTCAAGCTG 
Dl3M 
53POL 
·····~•'."'""""""""' 
O> 
0 
Figure 12. 
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Deduced amino acid sequence of the proposed 
dNTP and PPi binding site of the HCMV DNA 
polymerase protein. The right most number of 
the amino acid position is positioned above the 
corresponding amino acid. The homology to the 
HSV dNTP and PPi binding site is shown by a 
line above the AD169 sequence. Amino acid 
substitutions in the DlJ and H51853 proteins 
are shown below the AD169 sequence. Amino acid 
substitutions responsible for drug resistance 
in HSV are shown above the AD 16 9 sequence ( 4 9) . 
alanine A leucine L 
arginine R lysine K 
asparagine D methionine M 
aspartic acid B phenylalanine F 
cysteine c pro line p 
glutamine Q serine s 
glutamic acid E threonine T 
glycine G tryptophan w 
histidine H tyrosine y 
isoleucine I valine v 
HSV-1 
AD169 
D13M 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
HSV-1 
AD169 
DlJM 
53POL 
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T 545 
SPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCLQDAVL 
K V 595 
VRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDF 
645 
ILPNHYSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQ 
695 
SAPSSQDGVSPGSGSNSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVS 
s s 
HH S S 
G N 745 
YQGATVFEPEVGYYNDPVAVFDFASLYPSIIMAHNLCYSTLLVPGGEYPV 
795 
DPADVYSVTLENGVTHRFVRASVRVSVLSELLNKWVSQRRAVRECMRECQ 
T M M 5845 
DPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRIGRDML 
895 
ERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSG 
T 
945 
GSNERRVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEP 
VKL 
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the proposed PPi binding site in HSV. 
Isolation of a GCV-resistant clinical strain of HSV-2. 
An isolate of HSV-2 cultured from patient w.c. was obtained 
from the clinical microbiology laboratory at LUMC. HSV-2 
strain H6472 was isolated from a patient who was being treated 
with GCV for AIDS-related HCMV retinitis (Dr. J. Paul O'Keefe, 
personal communication) . Isolation of HSV-2 during GCV 
treatment suggested that strain H6472 might be re~istant to 
GCV. Stock virus was prepared and aliquots were stored at -
70°C. The antiviral susceptibility profile of the non-plaque 
purified virus was determined using the plaque reduction 
assay. Initial results using non-plaque purified virus 
revealed that strain H6472 was GCV- and ACV-resistant and PFA-
sensitive as compared to reference strain HSV-1 KOS (Table 5). 
The virus was twice plaque purified and clone CDl/1/1 was 
further characterized. 
Antiviral drug susceptibility testing of HSV-2 clone 
CDl/1/1. Antiviral drug susceptibility testing was performed 
on HSV-2 clone CDl/1/1 using the PRA. HSV-2 ATCC strain VR-
734 was used as the control virus. CDl/1/1 was both GCV- and 
ACV-resistant and PFA-sensitive (Table 6), confirming the 
results obtained using non-plaque purified virus. The 
susceptibility profile of CDl/1/1 was also determined using 
an ELISA assay for HSV-2. Though the numerical values for the 
ICSOs of GCV, ACV, and PFA were different than those obtained 
with the PRA, the susceptibility profile of CDl/1/1 remained 
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Table 5. Antiviral drug susceptibility profile of 
HSV-2 strain H6472. 
ICso (µM) 
Drug HSV-1 KOS HSV-2 H6472 
GCV 12.5 >500 
ACV 6.2 >50 
PFA 100 50 
Table 6. 
Drug 
GCV 
ACV 
PFA 
Antiviral drug susceptibility profile of 
HSV-2 strain H6472 clone CDl/1/1. 
ICso (µM) 
PRA ELISA 
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ATCC 74-3 CD/1/1/1 ATCC 74-3 CDl/1/1 
1. 6 
1.6 
100 
500 
125 
50 
0.03 
0.2 
125 
15.6 
1000 
125 
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the same. This susceptibility profile showing resistance to 
the nucleoside analogs and sensitivity to viral DNA polymerase 
inhibitors suggested that drug resistance was due to a 
mutation in the viral TK gene. 
site-directed in vitro mutagenesis of the HCMV AD169 DNA 
polymerase gene. Analysis of the nucleotide sequence of the 
viral DNA polymerase gene of HSV mutants resistant to DNA 
polymerase inhibitors has provided insight into the structure 
and function of the gene. Likewise, the effect of specific 
mutations on the expression of the cloned HSV polymerase gene 
has also been very useful. By introducing a specific mutation 
in the HCMV DNA polymerase gene followed by recombination of 
the mutated gene into the wild-type ·genome, we hoped to 
construct a recombinant drug-resistant strain of HCMV. A 
single base substitution was incorporated into the AD169 DNA 
polymerase gene using site directed mutagenesis. The AD169 
EcoRI M fragment was excised from pEcoM and inserted into the 
plasmid vector pSelect-1. Single strand template DNA template 
was prepared. An 18-mer oligonucleotide 5'-
GGCGCACAG~GTCTTGAC-3' containing a single guanine to thymine 
mismatch (underlined base) was annealed to the single strand 
template DNA and synthesis of the complementary strand was 
completed. Based on the published AD169 DNA polymerase 
nucleotide sequence (71), the resultant complementary sequence 
with the cytosine to adenine substitution at nucleotide 3048 
(see Figure 11) should encode a mutant enzyme with a threonine 
87 
(T) substituted for proline (P) at amino acid 797 (see Figure 
12). This mutation in the proposed dNTP and PPi binding site 
in the HSV DNA polymerase gene is thought to be responsible 
for ACV and PAA resistance in HSV ( 49) • The mutagenesis 
reaction yielded several hundred clones. Sequence analysis 
of 10 clones revealed that approximately 25% of the clones had 
incorporated the mismatch. Plasmid pTP03 was chosen for 
further study. Figure 13 shows the substitution of guanine 
for thymine at nucleotide number 3048 in the viral polymerase 
gene encoded on plasmid pTP03. 
Marker transfer between pTP03 and AD169 DNA. Previous 
work has shown that recombination can take place between viral 
sequences on plasmids and wild-type HSV DNA when both DNAs are 
co-transfected into permissive cells (11). We attempted to 
perform similar experiments in hopes of constructing a drug-
resistant HCMV. 
Preliminary studies showed that calcium phosphate-
media ted transfection of HFF with a plasmid encoding 
resistance to G418 yielded a very low percentage of G418-
resistant HFF cells. However, Vero cells transfected in a 
similar manner yielded a much higher percentage of G418-
resistant cells. Therefore, since transfection. of HFF was 
much less efficient than that of Vero cells, we anticipated 
a very low yield of recombinant drug-resistant HCMV. 
In several experiments, monolayers of HFF were co-
transfected with EcoRI-linearized pTP03 and HCMV stra·in AD169 
Figure 13. 
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Autoradiogram of the sequence of pTP03 showing 
the G to T substitution (underlined bases) at 
nucleotide number 3048. 
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genomic DNA. The monolayers were then incubated with medium 
alone, medium containing 12. 5 µM GCV or 600 µM PFA and 
monitored for the appearance of plaques. All transfections 
were unsuccessful, even those selected for in the absence of 
any drug. 
Recently, a second strategy was used for transfection of 
HFF. Slightly subconfluent monolayers of HFF were transfected 
with EcoRI-linearized pTPOJ. After several days incubation 
in growth medium when the cells reached conf luency, the 
monolayers were infected with HCMV strain AD169 at an MOI of 
1. One day post-infection, the cells were harvested by 
trypsinization and used to infect fresh HFF monolayers at an 
MOI of approximately o. 1. The infected monolayers were 
incubated in maintenance medium plus 0.3% agarose with and 
with out 12. 5 µM GCV. Substantial plaque formation was 
observed in the presence and absence of GCV. Several plaques 
from the plate containing GCV were picked and pooled in 1.2 
ml of maintenance medium. Six tubes of HFF were inoculated 
with 0.2 ml of virus suspension. Half were incubated in the 
presence of 12. 5 µM GCV. To date, several plaques can be seen 
in all tubes. However, the progression of plaque formation 
in tubes with GCV has been much slower than in tubes without 
GCV. 
Marker transfer between pTPOJ and HSV-1 DNA. pTPOJ 
contained a nucleotide subs ti tut ion in the HCMV AD169 DNA 
polymerase gene at a region which shows significant ,homology 
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to the HSV DNA polymerase gene (71). Therefore, we attempted 
marker transfer experiments in Vero cells using EcgRI-
linearized pTPOJ and wild-type HSV-1 KOS genomic DNA. Drug-
resistant virus was selected in the presence of 500 µM PFA. 
Several plaques were observed and picked for further 
characterization. 
Antiviral susceptibility testing using the PRA confirmed 
that clone PFAR5 was resistant to the DNA polymerase. inhibitor 
PFA (Table 7). The virus was also cross-resistant to the 
nucleoside analog ACV. This susceptibility profile suggested 
that a mutation in the viral DNA polymerase was responsible 
for drug resistance. However, at this point, it was not known 
whether the mutation was due to recombination event or whether 
it was a spontaneous event. 
Cloning of the HSV-1 strain PFAR5 DNA polymerase gene. 
The DNA polymerase gene of HSV-1 strain PFAR5 was cloned for 
further analysis. Clone PFAR5 viral DNA was isolated and 
digested with EcoRI, BglII, HindIII, and BamHI. The 
restriction enzyme profile of strain PFAR5 was identical to 
wild-type KOS (Figure 14). The carboxyl terminal portion of 
the HSV-1 KOS DNA polymerase protein is encoded on the EcoRI 
M fragment (50,51). This area of the protein shares maximum 
homology with human DNA polymerase a-like enzymes and contains 
the proposed HSV dNTP and PPi binding sites (49,50). 
Therefore, the PFAR5 EcoRI fragment migrating at the same 
position was excised, purified, and cloned into the pUC18 
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Table 7. Antiviral susceptibility profile of.HSV-1 
strain PFAR5. 
ICso (µM) 
Drug PFAR5 KOS 
PFA 1000 125 
PAA 800 200 
ACV 25 6.2 
HPMPA 6.2 3.1 
Figure 14. 
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Agarose gel of restriction endonuclease 
digested HSV-1 KOS and PFAR5. Sizes of the 
fragments in lanes 1 and 10 are 23.1,. 9.4, 6.6, 
4.4, 2.3, 2.0, and 0.6 kb. 
DNA: Lambda 
KOS 
PFAR5 
Enzymes: HindIII 
Eco RI 
BglII 
BamHI 
Lanes 1 and 10 
Lanes 2, 4, 6, 8 
Lanes 3, 5, 7, 9 
Lanes 1, 6, 7, 10 
Lanes 2 - 3 
Lanes 4 - 5 
Lanes 8 - 9 
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vector. Restriction analysis of transformant plasmid DNA and 
pSG17, a pBR325 derived clone containing the HSV-1 KOS EcoRI 
M fragment, revealed that two clones, pPFAR5Ml and pPFAR5Mll, 
contained the EcoRI M fragment inserted in opposite 
orientations (data not shown). 
Sequence analysis of the PFAR5 DNA polymerase gene. In 
order to locate the mutation in the PFAR5 DNA polymerase gene 
that might be responsible for drug resistance, the cloned 
PFAR5 DNA polymerase gene was then sequenced. Analysis was 
performed specifically on the areas thought to be involved in 
dNTP binding and PPi binding (amino acids 535-696 and 696-924, 
respectively, according to the published sequence of the KOS 
DNA polymerase gene (50). Mutations responsible for drug 
resistance of nine known HSV mutants have been mapped to this 
area. The published nucleotide sequence of this region of the 
HSV-1 KOS DNA polymerase gene and the deduced sequence of 
PFAR5 are shown in Figure 15. Nucleotide changes were 
observed at positions 2276, 2532, and 2534. There is also a 
triple deletion at positions 2295-2297. The amino acid 
sequences of HSV-1 KOS and PFAR5 deduced from the nucleotide 
sequence are shown in Figure 16. PFAR5 has a relatively non-
conservative threonine (T) to alanine (A) subl5titution at 
position 566, a substitution found in the ACV-resistant, PAA-
resistant mutant PFAr2 (48). However, PFAr2 also contained a 
conservative change from alanine (A) to valine (V) at position 
605, a change not seen in PFAR5. PFAR5 shows two adjacent 
Figure 15. 
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Nucleotide sequence of the proposed dNTP and 
PPi binding sites of the HSV-1 KOS and PFAR5 
DNA polymerase genes. The right most number 
of the nucleotide position is positioned above 
the corresponding base. Base subs ti tut ions and 
deletions in the PFAR5 gene are shown below the 
KOS sequence. 
2186 2278 
KOS CTCTCGAGCTACAAGCTCAACGCCGTGGCCGAAGCCGTCCTGAAGGACAAGAAGAAGGACCTGAGCTATCGCGACATCCCCGCTACTACGCCACC 
PFAR5 G 
2282 2373 
KOS GGGCCCGCGCAACGCGGGGTGATCGGCGAGTACTGCATACAGGATTCCCTGCTGGTGGGCCAGCTGTTTTTTAAGTTTTTGCCCCATCTGGAGCT 
PFAR5 
2377 2468 
KOS CTCGGCCGTCGCGCGCTTGGCGGGTATTAACATCACCCGCACCATCTACGACGGCCAGCAGATCCGCGTCTTTACGTGCCTGCTGCGCCTGGCCG 
PFAR5 
2472 2563 
KOS ACCAGAAGGGCTTTATTCTGCCGGACACCCAGGGGCGATTTAGGGGCGCCGGGGGGGAGGCGCCCAAGCGTCCGGCCGCAGCCCGGGAGGACGAG 
PFAR5 A G 
2567 2658 
KOS GAGCGGCCAGAGGAGGAGGGGGAGGACGAGGACGAACGCGAGGAGGGCGGGGGCGAGCGGGAGCCGGAGGGCGCGCGGGAGACCGCCGGCCGGCA 
PFAR5 
2662 2753 
KOS CGTGGGGTACCAAGGGGCCAAGGTCCTTGACCCCACTTCCGGGTTTCACGTGAACCCCGTGGTGGTGTTCGACTTTGCCAGCCTGTACCCCAGCA 
PFAR5 
2757 2848 
KOS TCATCCAGGCCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGGGCCGACGCAGTGGCGCACCTGGAGGCGGGCAAGGACTACCTGGAGATCGAG 
PFAR5 
2852 2943 
KOS GTGGGGGGGCGACGGCTGTTCTTCGTCAAGGCTCACGTGCGAGAGAGCCTCCTCAGCATCCTCCTGCGGGACTGGCTCGCCATGCGAAAGCAGAT 
PFAR5 
2947 3038 
KOS CCGCTCGCGGATTCCCCAGAGCAGCCCCGAGGAGGCCGTGCTCCTGGACAAGCAGCAGGCCGCCATCAAGGTCGTGTGTAACTCGGTGTACGGGT 
PFAR5 
3042 3133 
KOS TCACGGGAGTGCAGCACGGACTCCTGCCGTGCCTGCACGTTGCCGCGACGGTGACGACCATCGGCCGCGAGATGCTGCTCGCGACCCGCGAGTAC 
PFARS 
3137 3228 
KOS GTCCACGCGCGCTGGGCGGCCTTCGAACAGCTCCTGGCCGATTTCCCGGAGGCGGCCGACATGCGCGCCCCCGGGCCCTATTCCATGCGCATCAT 
PFARS 
3232 3323 
KOS CTACGGGGACACGGACTCCATATTTGTGCTGTGCCGCGGCCTCACGGCCGCCGGGCTGACGGCCATGGGCGACAAGATGGCGAGCCACATCTCGC 
PFARS 
3327 3352 
KOS GCGCGCTGTTTCTGCCCCCCATCAAACTC 
\0 
CX> 
Figure 16. 
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Deduced amino acid sequence of the proposed 
dNTP and PPi binding site of the HSV~l KOS and 
PFAR5 DNA polymerase proteins. The right most 
number of the amino acid position is positioned 
above the corresponding amino acid. Amino acid 
substitutions and deletions in the PFAR5 
protein are shown below the KOS sequence. 
Amino acid substitutions responsible for drug 
resistance in HSV are shown above the KOS 
sequence (49). Amino acid codes are listed in 
Figure 12. 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
KOS 
PFAR5 
100 
A 584 
LSSYKLNAVAEAVLKDKKKDLSYRDIPAYYATGPAQRGVIGEYCIQDSLL 
A 
K V 634 
VGQLFFKFLPHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLADQKGF 
684 
ILDPTQGRFRGAGGEAPKRPAAAREDEERPEEEGEDEDEREEGGGEREPE 
HE 
G N 734 
GARETAGRHVGYQGAKVLDPTSGFHVNPVVVFDFASLYPSIIQAHNLCFS 
784 
TLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRDWLAM 
T M M 834 
RKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVA 
s 884 
ATVTTIGREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIY 
924 
GDTDSIFVLCRGLTAAGLTAMGDKMASHISRALFLPPIKL 
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non-conservative substitutions, a histidine (H) for a proline 
(P) at position 651 and a glutamic acid (E) for lysine (K) at 
position 652. PFAR5 also has a triple nucleotide deletion in 
frame resulting in the deletion of glycine {G) at position 
572. 
DISCUSSION 
Development of the in situ ELISA for HCMV antiviral 
susceptibility testing. With the recent reports of the 
development of in situ ELISA assays for the determination of 
antiviral susceptibility of HSV (2,97), VZV (5) and 
respiratory syncytial virus (68), we modified this technique 
for use with HCMV. Data presented in this study demonstrated 
that the HCMV ELISA is rapid and reproducible, and showed good 
correlation with the standard plaque reduction assay. 
The ELISA assay objectively measures the level of a late 
HCMV nuclear antigen synthesized during a productive 
infection. The amount of this gamma protein is dependent on 
viral DNA synthesis (106) and, therefore, is directly 
proportional to the amount of viral replication. In contrast, 
the PRA measures the ability of an infectious particle to 
produce additional infectious progeny, which, in turn, infect 
adjacent cells forming a viral plaque. Plaque formation is 
determined visually and therefore is a subjective measurement. 
However, in the PRA, GCV-sensitive strains of HCMV tend to 
form single enlarged cells in wells containing concentrations 
of GCV higher than the IC50 • The infection does not spread to 
adjacent cells. It is difficult to determine the endpoint of 
the PRA because the amount of viral replication within single 
cells cannot be determined. Therefore, the ELISA appears to 
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be the more accurate assay for the measurement of inhibition 
of viral replication by GCV. 
The ELISA assay was more rapid than the PRA. IC50 values 
obtained in the PRA after 2 weeks incubation were obtained 
after only 1 week incubation in the ELISA. Also, if the MOI 
of the control and test virus was increased equivalently, the 
assay could be read in 3 to 4 days. Although the IC50 values 
of the control and test strains increased with the. shortened 
assay, the relative relationship between sensitive and 
resistant strains remained the same. 
The ELISA assay also detected resistance in cases where 
the PRA gave ambiguous results. GCV-resistant HCMV clones 
D13 and D16 were only 2-fold more resistant to the DNA 
polymerase inhibitors PFA and PAA as determined by the PRA 
(Table 4). Further testing using the ELISA showed that, in 
fact, both were clearly resistant to PFA and PAA (Table 4). 
Initial evaluation of the ELISA assay using the GCV-resistant 
kinase mutants D6/3/1 and Dl/3/4 did not show this phenomenon 
since both clones were PFA- and PAA-sensitive (Table 2}. No 
HCMV DNA polymerase mutants were available for testing during 
the initial studies. 
The ELISA assay was also able to detect a very small 
subpopulation of drug-resistant virus. GCV resistance in 
clinical strain H51856 was first detected using the ELISA 
assay (Table 3) . A percent survival assay performed to 
determine the percent of the population resistant to GCV 
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revealed that less than 1% of the population was GCV-
res istant. If the PRA had been used to screen the clinical 
isolates for drug resistance, only 20 to 40 infectious 
particles would have been used to inoculate a well (MOI = 
O. 001). Therefore, out of 80 to 160 possible plaques ( 4 wells 
per drug dilution), only o - 1 drug-resistant plaques would 
have been detected in the PRA. Calculations done to determine 
the IC50 for GCV in the PRA would have ignored this small 
number of GCV-resistant plaques and resulted in an IC50 
equivalent to wild-type HCMV strain AD169. Therefore, since 
the ELISA is inoculated using a 10-fold higher MOI (0.012), 
drug-resistant plaques may be detected more easily and more 
reliably than in ·the PRA. Also, progeny virus produced in the 
PRA do not spread farther than adjacent cells because of the 
semi-solid agarose overlay medium. In the ELISA, drug-
resistant progeny virus may spread to other areas of the 
monolayer for further infection and replication since the 
overlay is a liquid medium. Since the MOI of the ELISA can 
also be increased to allow shorter assay times, the amount of 
the drug-resistant sub-population per well would be increased. 
A definite drawback of the ELISA as well as th~· other 
assays described here is the requirement of extracellular 
virus for inoculation of cell monolayers. Numerous passages 
over a several month period are required for HCMV to become 
extracellular. Multiple passage may inadvertently cause 
selection of a sub-population of virus. Therefore, ·although 
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the ELISA assay may not be appropriate for the rapid screening 
of HCMV clinical isolates for drug resistance within the 
clinical microbiology laboratory setting, it would be a 
valuable assay for use in research and development. From the 
data presented in this study, the ELISA assay should 
supplement the PRA for the screening of the anti-HCMV activity 
of new antiviral agents. 
Telenti and Smith (118) recently described a rapid method 
to screen for GCV-resistance in HCMV. Shell vials containing 
MRC-5 cells are infected with extracellular HCMV in the 
presence of 20 µM GCV and incubated for 4 days. The 
coverslips are stained by an indirect fluorescent antibody 
procedure using a mouse monoclonal antibody to an early 
nuclear HCMV protein. Although this procedure is rapid, it 
appears to require extracellular virus, the measurement is 
subjective and the results are not quantitative. Also, 
detection of an early nuclear antigen measures only immediate 
or early events in the virus life cycle. Therefore, the assay 
cannot distinguish between an abortive infection with limited 
viral gene expression and true viral DNA replication. 
An enzyme immunocytochemical staining assay has been 
reported to determine HCMV infectivity (86). Although similar 
to the ELISA described here, monolayers in 24-well plates are 
stained with an alkaline phosphatase-conjugated antibody to 
a late viral antigen. The results are read visually using a 
microscope. Antiviral susceptibility testing using this 
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procedure would therefore be cumbersome and subjective. 
Four other assays recently developed for antiviral 
susceptibility testing of herpesviruses also measure DNA 
synthesis. Gadler et al. (47) employed a conventional DNA 
hybridization procedure using 32P-labeled probes which measured 
the effects of antiviral compounds on HCMV replication. HCMV-
infected cell monolayers in 24- or 96-well plates were 
incubated in the presence or absence of antiviral drugs. The 
cells were then harvested and placed on nitrocellulose 
filters. Following cell lysis and DNA denaturation, the 
filters , were hybridized with HCMV-specific probes. 
Hybridization was detected by autoradiography. A similar 
assay was described for VZV ( 114) • However, drawbacks of 
procedures which use 32P-labeled probes include the short half-
lif e of the label and the many tedious manipulations involved. 
Swierkosz et al. (117) modified this procedure for use with 
1251-labeled HSV probes and 96-well plates. The advantages of 
1251-labeled probes are a longer half-life and that 
hybridization can be measured objectively and more quickly 
using a gamma counter rather than by autoradiography. A HCMV 
hybridization assay for susceptibility testing also used 1251-
labeled probes (26). HFF in 24-well plates were infected with 
HCMV at a high MOl and incubated for 3-5 days until 3-4+ CPE 
was reached. The cells were lysed, DNA wicked onto membranes, 
and hybridized with a 1251-labeled HCMV DNA probe. Although 
all three procedures show good correlation to the PRA and are 
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more rapid, all involve the use of radioactivity. 
Characterization of GCV-resistant clinical isolate HCMV 
strain H51856. GCV susceptibility testing of 9 clinical 
isolates of HCMV revealed that strain H51856 was GCV-
resistant. This virus was isolated from the patient prior to 
any antiviral therapy. Parris and Harrington (94) have shown 
that HSV variants resistant to high concentrations of 
acyclovir exist in clinical isolates prior to . antiviral 
therapy and speculated that these ACV-resistant strains may 
be selected for during antiviral therapy. No similar studies 
have been conducted to date to determine the prevalence of 
GCV-resistant sub-populations in HCMV clinical isolates. 
Plaque dilution assays done here demonstrated that, in fact, 
H51856 contained a sub-population of GCV-resistant virus which 
comprised <1% of the total population. Erice et al. {39) 
described a . GCV-resistant HCMV isolated prior to GCV 
treatment. However, plaque dilution assays were not performed 
to determine if the isolate was actually a mixture of GCV-
resistant and GCV-sensitive virus. In this study, no drug-
resistant virus was isolated from the patient during or post-
treatment. Evidently, the small GCV-resistant subpopulation 
may not have been selected during therapy and may have been 
cleared naturally by the patient's immune system. 
Because of the life-threatening nature of the infection 
and because of promising in vitro susceptibility data, no 
controlled studies have been performed to determine the 
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efficacy of GCV treatment during HCMV disease in transplant 
patients. In fact, in certain clinical cases, HCMV infection 
has resolved without the administration of GCV. In this 
study, the patient who harbored strain H51856 which contained 
a GCV-resistant subpopulation remained culture-negative 
following GCV therapy. Thus, importance of the GCV-resistant 
subpopulation during therapy is questionable. 
Reports of ACV-resistant HSV isolated from patients who 
received long term ACV therapy suggest that antiviral therapy 
may select for the drug-resistant virus (6,23,40,75,102). Two 
reports have described the isolation of clinical strains of 
GCV-resistant HCMV from patients receiving GCV therapy 
although the biochemical and genetic basis of GCV resistance 
in these strains was not been determined (33,39). However, 
Erice et al. (39) also described a GCV-resistant clinical 
strain of HCMV (IC50 = 14.4 µM) isolated from a patient prior 
to GCV therapy. After 79 days of treatment, the HCMV isolated 
from the patient had become significantly more resistant (IC50 
= 30.5 µM). Restriction endonuclease patterns revealed no 
discernable differences between the two strains. 
Restriction endonuclease analysis of GCV-resistant 013 
and GCV-sensitive H51853 showed only very minor differences 
between the two strains (Figure 9). Since HCMV strains H51856 
and H51853 were isolated from the same patient from different 
sites on the same day, their strikingly similar restriction 
patterns suggests that the GCV-resistant strain may have 
arisen from mutation of the GCV-sensitive strain. 
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Several 
studies have used restriction endonuclease patterns to study 
the epidemiology of HCMV in AIDS patients (15,22,34,111,122). 
However, use of restriction endonuclease patterns for 
epidemiological purposes suffers from subjective 
interpretation. How many differences are necessary to call 
two strains unique? Huang et al. (64) demonstrated that HCMV 
isolates share 80-90% homology in their DNA content which 
would allow for considerable differences in sequence homology 
and restriction pattern. Also, it has not been determined if 
strain variation plays a role in drug resistance. Work is in 
progress to isolate and analyze the GCV-sensitive 
subpopulation of H51856. It will be interesting to see if the 
restriction pattern of this virus is more similar to clone D13 
than to strain H51853. 
GCV anabolism studies were performed to determine if the 
GCV-resistant clones D13 and D16 were able to phosphorylate 
GCV. Results showed that both clones were able to 
phosphorylate GCV at wild-type levels (Figures 6 and 7). 
These results in combination with the antiviral susceptibility 
patterns (Table 4) suggested that a mutation in the viral DNA 
polymerase gene was responsible for GCV resistance. This was 
very surprising since the majority of clinically isolated ACV-
resistant HSV strains are TK mutants (12) and not polymerase 
mutants. TK mutants may be more common since mutations in the 
viral TK gene are non-lethal (24). In contrast, mutations in 
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the viral DNA polymerase gene which result in a pol- phenotype 
are lethal. 
Sequence analysis of the GCV-resistant and GCV-sensitive 
HCMV DNA polymerase genes was performed on areas which show 
significant amino acid homology to the proposed dNTP and PPi 
binding sites of the HSV-1 DNA polymerase gene thought to be 
important in drug susceptibility (Figure 11). When compared 
to the wild-type HCMV strain AD169 sequence, only 4. of the 21 
nucleotide changes in the GCV-sensitive H51853 DNA polymerase 
gene resulted in altered amino acids (Figure 12). Two of 
these changes were shared by the GCV-resistant D13 DNA 
polymerase gene (positions 685 and 691). The other two would 
result in adjacent histidine substitutions at positions 651 -
652. The amino acids at HCMV positions 651 - 652 are not 
conserved in the HSV-1 or EBV sequences (69) and may not be 
critical for enzyme function and drug susceptibility. Three 
of the 21 nucleotide changes in the GCV-resistant D13 DNA 
polymerase gene would result in altered amino acids, the two 
shared by H51853 {positions 685 and 691) and a unique alanine 
(A) to threonine (T) substitution at HCMV amino acid position 
884. Since the A to T substitution at position 884 is the 
only unique substitution seen in the GCV-resistant polymerase 
gene, this amino acid change may be responsible for drug 
resistance in HCMV clone D13. Amino acid mutations resulting 
in a greatly changed secondary structure may produce a non-
functional protein and hence be a lethal mutation. Therefore, 
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since the GCV-resistant enyzme is functional, the threonine 
subs ti tut ion does not change or only slightly changes the 
secondary structure of the protein. 
This non-conservative change occurs in a 24 amino acid 
region {amino acids 880 - 904) of the HCMV polymerase protein 
not homologous to any sequences in the HSV-1 and EBV DNA 
polymerase proteins {71). These additional amino acids divide 
the region of the HCMV protein homologous to the HSV-1 dNTP 
and PPi binding sites {50, 71). Gaps such as these are 
identified by alignment of the HSV, HCMV, and EBV sequences 
to account for the different lengths of the three polypeptides 
and to generate maximum alignment of homologous amino acids. 
Two other additional amino acid regions also exist, both which 
also divides the region homologous to the dNTP and PPi binding 
sites. The actual dNTP and PPi binding sites in the HCMV 
enzyme may therefore be larger than in the HSV enzyme. Also, 
these non-homologous regions may be important for the 
structural integrity or protein folding of the HCMV enzyme. 
Analysis of mutants with small deletions in these areas or 
isolation of drug-resistant virus with mutations in these 
areas would provide valuable information. 
Several experiments should be performed to confirm that 
the A to T substitution at position 884 is responsible for 
drug resistance. Sequence analysis of the remaining areas of 
the 013 and H51853 polymerase genes should be completed to 
determine if any other amino acid changes exist that are 
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unique to the GCV-resistant enzyme. Marker rescue experiments 
can be carried out to construct recombinant HCMV. Monolayers 
of HFF should be co-transfected with EcoRI-linearized pD13M 
DNA and wild-type HCMV strain AD169 genomic DNA and incubated 
in the presence of GCV or PFA. Sequence analysis of drug-
resistant progeny would reveal if recombination actually 
occurred and if the A to T substitution was present. If the 
mutation is absent, then some other amino acid change in the 
D13 enzyme may have been transferred or a spontaneous mutation 
may have occurred. Also, site-directed mutagenesis should be 
performed on plasmid pEcoM introducing the A to T subs ti tu ti on 
at amino acid position 884. This plasmid construct can then 
be used in same type of marker ~escue experiments described 
above. Since the A to T substitution would be the only amino 
acid change in the mutagenized wild-type sequence, progeny 
which are drug-resistant should contain this specific change. 
Conversely, similar experiments constructing revertants back 
to the original sequence encoding the alanine at position 884 
should be drug-resistant. 
Once the GCV-sensitive subpopulation of H51856 is 
purified, sequence analysis of the DNA polymerase gene should 
be performed. One would expect that the nucleotide sequence 
should be nearly identical to the GCV-resistant clone Dl3 gene 
since they are subpopulations of the same isolate. Comparison 
of the these two sequences as well as the H51853 DNA 
polymerase sequence may provide more evidence as ·to which 
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amino acid is responsible for drug susceptibility. 
Biochemical analysis of the D13 enzyme should also be 
undertaken. In vitro assays have been described to measure 
the function of crudely purified HCMV DNA polymerase in the 
presence and absence of specific DNA polymerase inhibitors 
(8,46,79). Preliminary studies would assess the activity of 
the wild-type AD169 and D13 enzymes in the presence of PFA or 
PAA. One would expect the AD169 enzyme to be inhibited in the 
presence of PFA while the 013 enzyme should exhibit wild-type 
levels of activity in the presence of the inhibitor. Once 
expression vectors systems are developed for the HCMV DNA 
/ 
polymerase, the AD169 and D13 polymerase genes could then be 
cloned into plasmid expression vectors. Site directed 
mutagenesis would be performed on both plasmids yielding a 
wild-type AD169 protein with an A to T substitution at 
position 884 and D13 protein with T to A substitution at 
position 884. The in vitro expressed enzymes from all four 
constructs would then be assayed for activity in the presence 
and absence of DNA polymerase inhibitors. If the A to T 
substitution is responsible for drug resistance, then the 
enzyme expressed by the mutagenized AD169 construct containing 
the A to T substitution should be resistant to PFA. 
Conversely, the mutagenized 013 construct enzyme containing 
the corrected amino acid should be inhibited by PFA. Similar 
experiments have been done analyzing the role of specific 
amino acid residues in the HSV-1 TK gene (65) and the HSV-1 
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DNA polymerase gene (32,80,82). 
D'Aquila and Summers (28) have reported the isolation 
and characterization of laboratory-derived PAA-resistant 
mutants of HCMV. Since these mutants had PAA-resistant DNA 
polymerase activity in vitro, these workers hypothesized that 
mutations in the DNA polymerase gene may be responsible for 
drug resistance. These mutants were isolated by incubating 
HCMV strain AD169 in increasing concentrations of PAA thereby 
increasing the possibility that several mutations may have 
been introduced (61). However, since sequence analysis was 
not performed on the PAA-resistant viral polymerase genes, the 
site of the mutation(s) is unknown. 
Characterization of a GCV-resistant clinical isolate of 
HSV-2. A clinical strain of HSV-2 was isolated from a patient 
receiving GCV for AIDS-related HCMV retinitis. PFA treatment 
was eventually initiated and the HSV-2 and HCMV infections 
resolved. Other studies have reported isolation of ACV-
resistant HSV following ACV therapy which resolved following 
administration of PFA (13). Antiviral susceptibility testing 
of the initial isolate (Table 4) and a plaque purified clone 
(Table 5) revealed that the virus was resistant to GCV and ACV 
but not cross-resistant to PFA. This susceptibility profile 
suggested that GCV and ACV resistance was due to a mutation 
in the viral TK gene. Since the majority of drug resistant 
HSV strains are TK mutants (24), and these mutations have been 
characterized by sequence analysis (12,65,70), we chose not 
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to characterize this isolate any further. 
Mutaqenesis and marker transfer of the HCMV DNA 
polvmerase gene. A guanine to thymine subs ti tut ion was 
introduced in the HCMV DNA polymerase gene at nucleotide 3048 
by site directed mutagenesis (Figure 13} which would result 
in a proline (P} to threonine (T} substitution in the viral 
enzyme. Sequence analysis of PAA-resistant, ACV-resistant 
HSV-1 strain PAArC polymerase gene revealed a proline to 
threonine substitution at the homologous HSV position (49). 
Since the praline residue at this position is conserved 
between HSV-1, HSV-2, HCMV, and EBV as well as in human DNA 
polymerase a and yeast DNA polymerase I (49,121}, it may serve 
a critical function in enzyme activity and antiviral drug 
susceptibility. Marker rescue experiments using the 
mutagenized plasmid pTP03 were performed in order to construct 
recombinant drug-resistant HCMV virus. Numerous attempts were 
unsuccessful. This was not surprising for two reasons. 
First, preliminary experiments showed that the efficiency of 
HFF transfection in our laboratory is very low. In general, 
the efficiency of transf ection of primary cells is 10 to 100-
f old less than of cell lines (45). Secondly, the large size 
of the HCMV genome makes it difficult to isolate intact viral 
DNA. The isolation procedure may compromise the integrity of 
the viral chromosome thereby rendering the DNA non-infectious. 
Recently, the transfection procedure was modified and 
several GCV-resistant plaques have been isolated. Monolayers 
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of fibroblasts were transfected with plasmid DNA followed by 
infection with wild-type virus at an MOI of 1. This 
modification avoided the preparation and use of infectious 
viral DNA. The infected cells were then used to infect fresh 
monolayers of HFF. Plaques were selected in the presence of 
GCV. Once plaque purified, the antiviral susceptibility 
pattern of the clones will be determined. If recombination 
was successful, progeny virus should be GCV- . and PFA-
resistant. Sequence analysis will then reveal if the progeny 
are wild-type derived recombinant virus encoding the guanine 
to thymine substitution. 
Marker transfer experiments were also performed using 
the HCMV derived plasmid pTP03 and wild-type HSV KOS DNA since 
significant homology exists between the two viral DNA 
polymerase genes. One PFA-resistant plaque was observed and 
purified and clone PFAR5 was further characterized. The 
antiviral susceptibility profile revealed that clone PFAR5 
was resistant to PFA, PAA, and ACV, and marginally resistant 
to HPMPA (Table 6) . This phenotype suggested that a mutation 
in the viral pol gene was responsible for drug resistance. 
Sequence analysis of the dNTP and PPi binding sites suggested 
that PFAR5 was a spontaneous mutant since the nucleotide 
sequence (Figure 15) and theoretical amino acid sequence 
(Figure 16) were nearly identical to the parental HSV-1 KOS 
sequence. Several amino acid changes may be responsible for 
drug resistant phenotype. PFAR5 has a triplet deletion of 
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glycine at amino acid position 572. Since this deletion would 
not result in a frameshift, one would expect a nearly wild-
type length protein. However, the 3-dimensional configuration 
of the folded protein may be altered and prevent recognition 
and binding of the antiviral drug and substrate. A threonine 
(T) to alanine (A) substitution was seen at position 566. The 
T residue at this position in not conserved in HSV-2 (121), 
but surprisingly, an A residue is found in HSV-1.strain 17 
(96) , HCMV AD169 (71) , and EBV (71) . This variability 
suggests that the T or A residues at this position are not 
responsible for drug resistance. A proline (P) to histidine 
(H) and a lysine (K) to glutamic acid (E) substitution were 
seen positions 651 and 652, respectively. Amino acids at 
these positions are conserved in HSV-2 (96) and HSV-1 strain 
17 (96) but not in HCMV or EBV (71). These substitutions 
alone or combined may be responsible for drug resistance. 
Marker rescue experiments similar to those described for GCV-
resistant HCMV clone D13 using the cloned PFAR5 DNA polymerase 
gene should be performed. Similar additional experiments 
using a mutagenized wild-type KOS gene containing the specific 
nucleotide substitutions seen in PFAR5 would yield valuable 
information. 
Future design of new anti-herpesvirus agents. This study 
described a molecular analysis of the first reported 
clinically isolated drug-resistant DNA polymerase mutant of 
HCMV. A DNA polymerase mutant of HSV-1 was also described. 
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Further characterization of wild-type and mutant herpesvirus 
DNA polymerase genes should benefit in the design of more 
effective anti-herpesvirus agents. Characterization of more 
drug-resistant mutants and expression of mutated cloned 
enzymes will more clearly define the areas of the enzyme 
involved in drug interaction. Interactions of the DNA 
polymerase and template DNA with cellular proteins can also 
be studied in more detail. X-ray crystallography of the 
purified enzymes will shed light on the structure of the 
enzymes. Since the sequences of the enzymes have been 
determined, computer models of their structures 
correlated to the X-ray crystallography results. 
could be 
With the 
aid of computer modeling, it may now possible to· design 
specific inhibitors targeted to unique sites of purified 
viruses or their associated enzymes (59). 
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